

CURRICULUM VITAE

NAME: GRAEME FINLAY MASON
 TITLE: Professor
 Birth date: March 16, 1963
 Birth place: Glasgow, Scotland
 Citizenship: U.S.A.

EDUCATION

Institution	Degree	Year	Field of Study
Yale University New Haven, CT	Ph.D.	1991	Molecular Biophysics & Biochemistry
The Pennsylvania State University State College, PA	B.S. Minor	1986	Nuclear Engineering with Honors Spanish

RESEARCH AND PROFESSIONAL EXPERIENCE

2012-Present Professor, Yale University School of Medicine, Departments of Radiology & Biomedical Imaging and Psychiatry, Biomedical Engineering (2019-present)
 2023-Present Coordinator of YCCI/MRRC Joint Outpatient Bed unit
 2006-2012 Associate Professor, Yale University School of Medicine, Departments of Diagnostic Radiology and Psychiatry, Division of Bioimaging Sciences
 2003-2006 Associate Professor, Yale University School of Medicine, Departments of Psychiatry and Diagnostic Radiology, Division of Bioimaging Sciences
 2002-Present Director of Metabolic Modeling, Director of Psychiatric MRS, Yale Magnetic Resonance Research Center, Yale University, School of Medicine
 2006-Present Director, Neuroimaging Sciences Training Program, Yale University
 1997-2003 Assistant Professor, Yale University School of Medicine, Dept. of Psychiatry
 Director of the Psychiatric Magnetic Resonance Spectroscopy
 Joint Appointment, Department of Bioimaging Sciences Program
 New Haven, CT
 1995-1997 Assistant Professor, University of Alabama at Birmingham, Dept. of Medicine, Div. of Cardiovascular Disease, Center for Nuclear Imaging Research, Birmingham, AL (joint appointment with Biomedical Engineering, 1997)
 1994-1995 Instructor, University of Alabama at Birmingham, Dept. of Medicine
 1993-1994 Postdoctoral Fellow, University of Alabama at Birmingham, Dept. of Medicine, Center for Nuclear Imaging Research, Birmingham, AL
Mentor: Dr. Hoby P. Hetherington
 1991-1993 Postdoctoral Research Associate in the laboratory of Professor Robert G. Shulman
 Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT
 1986-1991 Graduate Study, Department of Molecular Biophysics & Biochemistry
 Yale University, New Haven, CT
Ph.D. Thesis Research Topic: Nuclear magnetic resonance studies of cerebral glucose transport and metabolism *in vivo*
Thesis Advisor: Professor Robert G. Shulman
 1986 (summer) Research Assistant in Nuclear Magnetic Resonance, Hershey Medical Center
Supervisor: Dr. Richard Briggs
 1985 and Co-op Engineer at Boiling Water Nuclear Reactor
 1984 (summer) Susquehanna Steam Electric Station; Plant Engineering and Technical Compliance Groups; Pennsylvania Power & Light Company

HONORS

1986-1991 NIH Graduate Fellowship
 1986 National Science Foundation Fellowship Honorable Mention
 1984-1986 Institute of Nuclear Power Operations (INPO) Scholarship

- 1984-1986 John White Scholarship for Excellence in Spanish
- 1991 & 1992 Student Travel Awards, Society of Magnetic Resonance in Medicine
- 1997 Invited to Chair Session on ¹³C Magnetic Resonance Spectroscopy at *Brain Energy Metabolism* satellite meeting to Society of Neurochemistry, Waterville Valley, NH
- 1998-2000 Stanley Foundation Young Investigator Award
- 2000-2002 NARSAD Young Investigator Award
- 2000 Honorable Mention – alternate for Memorial Travel Award for American College of Neuropsychopharmacology
- 2002-2004 NARSAD Young Investigator Award
- 2002 American College of Neuropsychopharmacology Memorial Travel Award
- 2003,2004 Editor’s Recognition Award for Reviewing with Special Distinction, *Radiology*
- 2015 Elected Senior Fellow, *International Society of Magnetic Resonance in Medicine*
- 2015 Promoted to Fellow, *American College of Neuropsychopharmacology*
- 2007,2011, Editor’s Recognition Award for Reviewing, *Biological Psychiatry*, Top 10 reviewers.
- 2012,2014,2015,
- 2016,2017,2019,
- 2020
- 2018 Inducted into the Academy Distinguished Investigator Council of the Academy for Radiology & Biomedical Imaging Research
- 2022 Editor’s Recognition Award for Reviewing, *Neuropsychopharmacology*, Top 10 reviewers.
- 2023 Top Reviewer for *Neuropsychopharmacology*
- 2024 Inducted into the Muncy High School Academic Hall of Fame

TEACHING

- 2023,2024 Organized the course, *Establishing a Thriving Research Program*, together with Rajita Sinha at the Office of Physician-Scientist Development, Yale School of Medicine, July 25-August 17, 2023, and again March 12-May 7, 2024. This course teaches postdoctoral trainees and junior faculty on practicalities of starting and running a research laboratory.
- 2022 Yale Janeway Society Lecture, joint with Todd Constable, “Practicalities of Getting Your First Funding and How to Write Your First R01”, February 4, 2022.
- 2022,2023 Co-organizer of Yale Conference for Alcohol Research & Education Sept 10, 2022 and Sept 30, 2023
- 2021 Yale Center for Clinical Investigation’s Lecture, joint with Rajita Sinha, “How to run a research lab”, July 19, 2021
- 2021 Organized the course, *Basic Statistical Methods in Psychiatry*, a 5-session course taught by Ralitzha Gueorguieva over 5 weeks, for Radiology and Psychiatry faculty, fellows, postdocs, students, and staff. Over 150 registrants.
- 2001-present Created, organized, and team-taught *Physics of Magnetic Resonance* (Now listed as Yale Engineering and Applied Sciences 825). The lecture notes take advantage of the electronic media by using computer animations of dynamic processes such as radiofrequency pulse effects and isotopic tracer behavior during kinetic metabolic experiments.
- 2019 Created and organized *Establishing a Thriving Research Program*, a 4-day intensive course for postdocs and junior faculty on practical aspects of establishing and managing a lab. offered to postdoctoral trainees and junior faculty on how to run a research laboratory. The course covers management of personnel, finances, grants issues, negotiations for startup packages, and dissemination of ideas and results.
- 1997-2000 Organized Psychiatric Biochemistry Seminar, a weekly meeting designed (1) to foster contacts and collaborations between the Yale Department of Psychiatry and laboratories equipped with particular expertise to study brain chemistry (2) to educate technique-based investigators and biochemists about current questions in psychiatry, and (3) to educate Psychiatry-based investigators about the abilities and limitations of investigative methods, particularly magnetic resonance spectroscopy and imaging. The series consists of members of Yale Psychiatry and members of collaborative or potentially collaborative laboratories.
- 1997-2002 Organized the Neuroimaging Sciences Training Program Lecture Series, a bi-weekly series

designed to educate fellows in the Yale Psychiatry's Neuroimaging Sciences Program in a variety of neuroimaging techniques, focusing when possible on multi-modality imaging. Speakers external to Yale were invited and hosted by members of Psychiatry, the Magnetic Resonance Center, and the Child Study Center. The speakers are asked to include in both didactic and research components in their Presentations.

PROFESSIONAL ACTIVITIES

- Member, American College of Neuropsychopharmacology, Research Society on Alcoholism, Society of Biological Psychiatry; International Society of Magnetic Resonance in Medicine; International Drug and Alcohol Research Society; Tau Beta Pi engineering national honor society; Alpha Nu Sigma nuclear engineering honor society (affil. American Nuclear Society)
- Research Society on Alcoholism*: Program Committee (2006-2008), Research Priorities Committee (2008), Education Committee member (2011-2022), Chair of Gordis Awards subcommittee of Education Committee (2014-2018), Vice-Chair Education Committee (2017-2018), Chair Education Committee (2018-2020), Past-Chair Education Committee (2020-2022). (2020 - ongoing) Developed two video libraries for the *Research Society on Alcoholism*, one of long videos for alcohol researchers, the other of shorter introductory videos for recent entrants to the field of alcohol research, to teach about the full field of alcohol research, physiology, health disparities, public policy, treatments, and more. Board of Directors (2023-2027).
- Editorial Board of *Biological Psychiatry*, 2002-present
- Editorial Board Member of *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 2015-present
- Field Editor, *Alcohol: Experimental and Clinical Research*, 2016-present
- Editorial Board Member of *Neuropsychopharmacology*, 2018-present
- Reviewer for *Alcoholism: Clinical and Experimental Research*, *American Journal of Physiology*, *Alcohol and Alcoholism*, *Annals of Biomedical Engineering*, *Archives of General Psychiatry*, *Biological Psychiatry*, *Bipolar Disorders*, *Biotechnology Progress*, *Brain*, *Brain Research*, *Cerebral Cortex*, *Drug and Alcohol Dependence*, *Epilepsia*, *International Journal of Imaging Systems and Technology*, *Journal of Applied Physiology*, *Journal of Alzheimer's Disease*, *Journal of Biological Chemistry*, *Journal of Cerebral Blood Flow & Metabolism*, *Journal of Clinical Investigation*, *Journal of Engineering in Medicine*, *Journal of Magnetic Resonance*, *Journal of Neurochemistry*, *Journal of Neuroscience*, *Journal of Neuroscience Methods*, *Journal of Psychiatry & Neuroscience*, *Magnetic Resonance Imaging*, *Magnetic Resonance in Medicine*, *Medical Image Analysis*, *Neuropsychopharmacology*, *Neuroscience Letters*, *Neuroscience Research*, *NMR in Biomedicine*, *Proceedings of the National Academy of Sciences USA*, *Psychiatry Research: Neuroimaging*, *Psychological Medicine*, *Psychopharmacology*, *Radiology*, *Schizophrenia Bulletin*
- Member Neurotoxicity and Alcoholism (NAL) Study Section for NIH/NIAAA 2012; Member Neuropathology of Addiction and Sleep Disorders (NPAS) Study Section for NIH/CSR 2014-2016; Ad hoc grant reviewer for other NIH Review Sections; Alberta Heritage Foundation for Medical Research; Austrian Science Foundation; Center for Medicinal Cannabis Research; Children's Hospital of Michigan – Wayne State University; Chronic Fatigue and Immune Dysfunction Syndrome Foundation; HIV Neurobehavioral Research Center; Idaho State Board of Education; South Carolina EPSCoR Program; U.S.-Israel Binational Science Foundation; Gutenberg Chair Program, Strasbourg 2018; Clinical Translational Science Awards (NIH CTSA) 2013, 2017, 2018
- Member Neuroscience & Behavior Study Section AA-4 for NIH/NIAAA, 2017-2023
- Member Scientific Advisory Board for the Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) Association of America (2005-2009)
- July 23, 1997 *Brain Energy Metabolism* satellite to *Neuroscience* meeting. Organized and chaired discussion session entitled "Metabolic Modeling of ¹³C Labeling".
- May 5, 2001 Organized and chaired the symposium "Cortical GABA in Disease and Function" at the annual meeting of the *Society of Biological Psychiatry*, New Orleans, LA.
- Dec 12, 2001 Organizer and chair of study group entitled, "Use of the ¹³C-Labeled Tracers in MRS to Characterize Neuron-Glia Interactions in Glutamatergic and GABAergic Neurotransmission: Psychiatric Applications", at the annual meeting of the *American College of Neuropsychopharmacology* (Waikoloa, Hawaii).

2001-2003 Conceived and organized Psychiatric Magnetic Resonance Study Group under the International Society of Magnetic Resonance in Medicine (ISMRM).

2003-2005 Chair of Psychiatric MR Study Group of the ISMRM

2005-2006 Past Chair of Psychiatric MR Study Group of the ISMRM

2003-2005 Member of the Study Group Review Committee, ISMRM

2002-2003 Member, organizing committee for the Symposium on Neuroimaging in Alcoholism, Jan 12-14, 2003, New Haven, CT, in collaboration with the Yale Center for Translational Neuroscience in Alcoholism.

2004-2008 Member, Education Committee of Center for Translational Neuroscience in Alcoholism

2004-2005 Co-Chair, organizing committee for the ISMRM Workshop on Magnetic Resonance Spectroscopy for Neuropsychiatric Disorders, October 14-17, 2005, Banff, Alberta, Canada

2006 External Examiner for Ph.D. defense of Atiyah Yayha, in the laboratory of Peter Allen, Ph.D., of the University of Alberta, Department of Biomedical Engineering

2005-2008 Chair, organizing committee for the ISMRM Workshop on Magnetic Resonance Imaging and Spectroscopy for Neuropsychiatric Disorders, November 7-10, 2008, Quebec, Canada

2007-2008 Member, organizing committee for the Symposium on Neuroimaging in Alcoholism, Jan 12-14, 2008, New Haven, CT, in collaboration with the Yale Center for Translational Neuroscience in Alcoholism.

2007-2008 Ad-Hoc Presidential Appointee to Study Group Review Committee, ISMRM

2007 Chair and Organizer, Panel entitled “Smoking and GABA: an Avenue to Quit?”, *American College of Neuropsychopharmacology*, Boca Raton, Florida

2008 Co-chair of Educational Series, *Espectroscopia por Ressonância Magnética, Congresso IBRO/LARC de Neurociências da América Latina, Caribe, e Península Ibérica*, Sept 1-4, Búzios, Brazil

2009 Member, review group for ISMRM poster awards for Psychiatric MR Study Group

2009 Chair, Panel entitled “Efectos Neuroquímicos de Étanol y Nicotina”, *16º Congreso Internacional de Psiquiatría*, Buenos Aires, Argentina

2011-2014 Member, Program Committee for the 2012 and 2013 annual meetings of the Society of Biological Psychiatry

2012-2014 Chair-Elect, then Chair Psychiatric MR Imaging and Spectroscopy Study Group, ISMRM

2012 Organized and chaired the symposium “Quantitative fMRI in neuropsychiatry - the importance of BOLD change” at the annual meeting of the *Society of Biological Psychiatry*, Philadelphia, Pennsylvania, May 3

2013 Co-Chair, organizing committee for the ISMRM Workshop on Magnetic Resonance Imaging and Spectroscopy for Neuropsychiatric Disorders, September 7-10, 2013, Lisbon, Portugal

2019 Co-Chair and organizer of Symposium at Research Society on Alcoholism, *Alcohol Metabolism and the role of Ketone Bodies to Alleviate Symptoms of Alcohol Withdrawal*

2014-2019 Member, Scientific Advisory Board for Alcohol Center, Medical University of South Carolina

2016-2020 Member, Education Committee, American College of Neuropsychopharmacology

2017-present Member, Scientific Advisory Board for *Drug Abuse and Brain Imaging Training Program (DABITP)*, McLean Hospital, Boston, MA

2020-present Organized, Recorded RSA Lecture Series (professional and public formats) on Alcohol for the Research Society on Alcoholism

2019-present Member, Internal Advisory Board, University of Pennsylvania/Yale PET Addiction Center of Excellence (PACE)

2021 Organizer, Chair of symposium *How to Tell Your Story: Strategies for Trainees, Research Society on Alcoholism*, June 21

2022 Co-Organizer of Yale Conference for Alcohol Research and Education (Y-CARE), September 10, an educational CME program for local clinicians and researchers. (with David Fiellin, M.D. and Principal Organizer Bubu Babini, M.D., Ph.D.)

2023 Co-Organizer of Yale Conference for Alcohol Research and Education (Y-CARE), September 30, an educational CME program for local clinicians and researchers. (with David Fiellin, M.D., Sherry McKee, and Principal Organizer Bubu Babini, M.D., Ph.D.)

2024 Gordon Research Conference on Alcohol, Feb 11-16. Discussion Leader for *Cellular, Molecular and System Level Effects of Alcohol*, Galveston, TX

2024- Member, Scientific Advisory Board for Alcohol Center, Medical University of South Carolina
2024- Member, External Program Advisory Committee for Portland Alcohol Research Center, Oregon
Health & Science University

DEPARTMENTAL, MEDICAL SCHOOL, AND UNIVERSITY COMMITTEES

Yale Human Investigation Committee (IRB) (member 2000-2004, consultant 2004-present)

2005-present Founder and Chair, Magnetic Resonance Research Center (MRRC) Protocol Review Committee

LANGUAGES

Fluent in English, Spanish, and Portuguese; functional in French

RESEARCH INTERESTS

1. ^{13}C and ^2H isotopic labeling studies of brain metabolism.

Since 1988, I have been developing experimental models and methods for studies of brain metabolism using ^{13}C NMR in conjunction with ^{13}C isotopic labeling *in vivo*. The work began during my graduate studies at Yale, with the experimental determination of brain glucose transport kinetics and substrate competition for oxidative brain metabolism in a rat model. The work continued through my training at the University of Alabama at Birmingham, where I guided the group's ^{13}C -labeling studies of the human brain *in vivo* in the 4.1T whole-body MR system. I continue studies of the metabolism and neurotransmission in the human and animal brain *in vivo*, studying healthy subjects and patients with neuropsychiatric disorders to investigate relationships among GABA, glutamate, and glutamine concentrations and their rates of synthesis and release in the brain.

2. Mathematical modeling analysis of biochemical pathways.

My major research interest has been the development and application of mathematical models for the determination of rates of metabolism and enzyme kinetics from ^{13}C NMR isotopic labeling experiments. The approach I have taken has been to integrate the modeling development into the design of experimental protocols by determination of the sensitivities of the calculated rates to the measured and assumed parameters of the system. The sensitivities are used to determine which parameters are critical to control or measure in particular experiments to obtain accurate results.

With the continuing development of improved NMR methods for isotopic analysis, I am extending the modeling through inclusion of additional pathways, as well as developing models for other metabolic systems, including liver, tumor cells, skeletal muscle, and pancreatic islet preparations. In addition, I plan to integrate the kinetic information with metabolic control analysis of the pathways for quantitative evaluation of metabolic regulation *in vivo*.

3. Neurotransmission in psychiatric diseases.

I develop and apply MRI and MRS methods together with mathematical analyses to understand the chemical bases of psychiatric disorders. My current focus is on alcoholism and its effects on brain metabolism and behavior.

A common path to understanding a system is to perturb it and measure its responses. Psychiatric disorders provide cases of perturbed brain function and chemistry that can be studied by MRS to provide quantitative input for the mathematical understanding of the regulation of brain metabolism. Another approach is to use pharmacologic challenges of brain metabolism and function with substances such as alcohol, simultaneously obtaining information that may be of use in understanding abuse and addiction to these substances.

GRANTS (P.I.)

Completed

1. **Intermediary Metabolism in Alzheimer's Disease.**
Source: Pilot grant from the Alzheimer's Disease Center,
University of Alabama at Birmingham
Effective dates: 7/1/94-6/30/95
Role: P.I.
Total Amount: \$20,000

2. **NMR Studies of GABA Metabolism and Regulation in vivo**
Source: NIH/Yale University (KL Behar, P.I./G.F. Mason, P.I. at UAB)
Effective dates: 4/1/96-9/13/97
Role: Local P.I.
Amount of Salary: 10%

3. **Clinical NMR Studies at 4.1T - A Research Resource**
Source: NIH (HP Hetherington, P.D.) 1-P41-RR11811-01
Effective dates: 3/01/97-2/29/00 (discontinued 9/13/97 due to move to Yale)
Role: P.I. of Core V (Modeling and Experiment Design)
Total Direct: \$245,144
Total Indirect: \$107,863
Total Cost: \$353,007
Amount of Salary: 44%

4. **Mechanism of the Reduction of Cortical GABA in Unipolar Depression and Bipolar Disorder**
Source: The Stanley Foundation
Effective dates: 7/1/98-6/30/00
Role: P.I.
Total Costs: \$149,000
Amount of Salary: 20%

5. **Mental Health Clinical Research Center**
Source: NIH/NIMH
Effective dates: 10/01/93 - 9/30/98
Role: P.I. of MR Spectroscopy Core
Total Costs: \$120,000
Amount of salary: 20%

6. **Cortical GABA in Unipolar and Bipolar Depression**
Source: NARSAD Young Investigator Award
Effective dates: 7/1/00 – 6/30/02
Role: P.I.
Total Costs: \$60,000
Amount of salary: 20%

7. **Thalamocortical Glutamatergic Function: Relationship to GABA Deficits in Depressed Patients**
Source: NARSAD
Effective dates: 7/1/02 – 6/30/05
Role: P.I.
Total Costs: \$60,000

8. **Nicotine Effects on Human Cortical Glutamate and GABA**
Source: CENTURY (Yale Nicotine Center Pilot Project)
Effective dates: 9/30/03-8/31/05
Role: P.I.

Total Costs: \$25,000

9. **¹³C MRS Studies of Prefrontal Cortical Glutamate Release (Project 3 of NIAAA Center)**
Source: National Institutes of Health (NIAAA)
Effective dates: 6/1/01 – 5/31/06
Role: P.I. of Project 3
Total Costs: \$500,000 for Project 3
10. **Development of Non-Occipital, Multi-Volume GABA MRS at 4 Tesla**
Source: Pfizer, Inc. (Graeme Mason)
Effective dates: 1/1/05-12/31/06
Role: P.I.
Total Costs: \$376,000
11. **Recovery of Cortical GABA Systems with Sobriety: a Multimodality Study: Alcoholism Research Center**
Source: VA Healthcare Systems
Effective dates: 1/1/00 – 12/31/05
Role: P.I., Magnetic Resonance Imaging Division
Total Costs: \$1,600,000
12. **Quantitative MR Imaging and Spectroscopy in Alcoholism (NIAAA 1K02AA13430)**
Source: National Institutes of Health (NIAAA)
Effective dates: 5/1/02 – 10/31/07
Role: P.I.
Total Costs: \$ 510,854
13. **Brain MRS of Healthy Subjects Family History Positive and Negative for Alcoholism**
Source: National Institutes of Health (NIAAA), pilot project in CTNA-2 (Center for Translational Neuroscience of Alcoholism)
Effective dates: 6/1/06 – 5/31/08
Role: P.I. of project (J. Krystal PI of Center)
Total Costs: \$ 50,000
14. **Neurotransmitter Function, Psychiatric Disorders, & MRS (NIMH R13 MH080581)**
Source: National Institutes of Health (NIMH)
Effective dates: 9/1/07-3/15/09
Role: P.I.
Total Costs: \$15,000
15. **Imaging Nicotinic & GABAergic Markers in Tobacco Smokers (NIAAA P50-AA1532)**
Source: National Institutes of Health, Project 2 of the Yale Transdisciplinary Tobacco Use Research Center (TTURC)
Effective dates: 1/1/05-12/31/10
Role: co-P.I.
Total Costs: \$1,051,099
16. **GABA and Glutamate Impact of Genetic Vulnerability to Alcoholism**
Source: Dana Foundation
Effective dates; 9/1/05-8/31/10
Role: P.I.
Total Costs: \$100,000
17. **Role of Acetate in Heavy Drinking (NIAAA R21 AA018210)**
Source: National Institutes of Health (NIAAA)

Effective dates: 4/15/09-4/14/12
Role: P.I.
Total Costs: \$742,500

18. Ethanol as Fuel for the Brain in Rats (NIAAA R21 AA019803)

Source: National Institutes of Health (NIAAA)
Effective dates: 7/10/10-6/30/13
Role: P.I.
Total Costs: \$439,405

19. GABA Effects of Nicotine in Men and Women (NIDA R01 DA021785)

Source: National Institutes of Health (NIDA)
Effective dates: 1/15/09-11/30/13
Role: P.I.
Total Costs: \$1,856,250

20. Neuroimaging Sciences Training Program (NIDA T32 DA022975)

Source: National Institutes of Health (NIDA)
Effective dates: 7/1/07 – 6/30/13
Role: P.I.
Total Costs: \$1,214,000

21. Neuroimaging Sciences Training Program (NIDA T32 DA022975)

Source: National Institutes of Health (NIDA)
Effective dates: 7/1/14 – 6/30/19
Role: P.I.
Total Costs: \$1,286,017

22. Brain Acetate and Ethanol Metabolism in Alcohol Dependence and Abuse (R01 AA021984)

Source: National Institutes of Health (NIAAA)
Effective dates: 7/15/13-6/30/19
Role: P.I.
Total Costs: \$2,747,021

23. Neuroimaging Sciences Training Program (NIDA T32 DA022975)

Source: National Institutes of Health (NIDA)
Effective dates: 7/1/19 – 6/30/24
Role: P.I.
Total Costs: \$1,853,358

24. Relationship of Brain Ethanol Oxidation with Behavior (R21 AA028628)

Source: National Institutes of Health (NIAAA)
Effective dates: 9/1/20-6/30/22
Role: P.I.
Total Costs: \$453,750

25. Comprehensive, Cross-Platform Validated 13C Flux Measures of Intra- and Inter Tissue Metabolism (R01 DK108283) (co-PI with R. Kibbey)

Source: National Institutes of Health (NIDDK)
Effective dates: 7/1/16-6/30/20
Role: P.I. (Co-P.I. with R. Kibbey)
Total Costs: \$2,601,880

Active

1. Chronic Alcohol, Dementia, and CNS Fluid Homeostasis (R01AA030183)

Source: National Institutes of Health (NIAAA)
Effective dates: 9/1/2022 - 8/31/2027
Role: P.I. (co-P.I. with H. Benveniste)
Total Costs: \$2,456,527

2. **Drinking, Brain Acetate, and Stress** (R01 AA031401)

Source: National Institutes of Health (NIAAA)
Effective dates: 3/15/2024 - 1/31//2029
Role: P.I.
Total Costs: \$3,409,550

3. **Neuroimaging Sciences Training Program** (T32 DA022975)

Source: National Institutes of Health (NIDA)
Effective dates: 7/1/24 – 6/30/29
Role: P.I.
Total Costs: \$3,209,874

PATENTS

Techniques of mass spectrometry for isotopomer analysis and related systems and methods (2020) US Patent 10,770,276) Richard Kibbey, Tiago Cardoso Alves, **Graeme F. Mason**

PUBLICATIONS

1. **Mason GF**, Rothman DL, Behar KL, Shulman RG (1992) NMR determination of TCA cycle rate and α -ketoglutarate/glutamate exchange rate in rat brain. *J Cereb Blood Flow Metab* 12: 434-447
2. **Mason GF**, Behar KL, Rothman DL, Shulman RG (1992) NMR determination of intracerebral glucose concentration and transport kinetics in rat brain in vivo. *J Cereb Blood Flow Metab* 12: 448-455
3. Gruetter R, Novotny EJ, Boulware SD, Rothman DL, **Mason GF**, Shulman GI, Shulman RG, Tamborlane WV (1992) Direct measurement of brain glucose concentrations in humans by ^{13}C NMR spectroscopy. *Proc Natl Acad Sci USA* 89: 9603-9606 PMID: PMC48395
4. Rothman DL, Novotny EJ, Shulman GI, Howseman AM, Petroff OAC, **Mason GF**, Nixon T, Hanstock CC, Prichard JW, Shulman RG (1992) ^1H - ^{13}C NMR measurements of $[4\text{-}^{13}\text{C}]$ -glutamate turnover in human brain. *Proc Natl Acad Sci USA* 89: 9603-9606
5. **Mason GF**, Behar KL, Martin MA, Shulman RG (1993) Rat brain glucose concentration and transport kinetics determined with ^{13}C nuclear magnetic resonance spectroscopy, in *Frontiers in Cerebral Vascular Biology: Transport and its Regulation*, Plenum Press, New York (ed. Drewes LR and Betz AL), 331: 29-34
6. Gruetter R, Novotny EJ, Boulware SD, Rothman DL, **Mason GF**, Shulman GI, Tamborlane WV, Shulman RG (1993) Non-invasive measurements of the cerebral steady-state glucose concentration and transport in humans by ^{13}C nuclear magnetic resonance, in *Advances in Experimental Medicine and Biology*, Plenum Press, New York (ed., Drewes LR and Betz AL), 331: 35-40
7. Price TB, Taylor R, Shulman GI, **Mason GF**, Rothman DL, Shulman RG (1994) Turnover of human muscle glycogen during low intensity exercise. *Med Sci Sports and Exercise* 26: 983-991
8. Hetherington H, Pan JW, **Mason GF**, Ponder SL, Twieg DB, Deutsch G, Mountz J, Pohost GM (1994) 2D spectroscopic imaging of the human brain at 4.1T. *Magn Reson Med* 32: 530-534
9. Hetherington HP, **Mason GF**, Pan JW, Ponder SL, Vaughan JT, Twieg DB, Pohost GM (1994) Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. *Magn Reson Med* 32: 565-571
10. **Mason GF**, Pan JW, Ponder SL, Twieg DB, Pohost GM, Hetherington HP (1994) Detection of brain glutamate and glutamine in spectroscopic images at 4.1T. *Magn Reson Med* 32: 142-145
11. Gruetter R, Novotny EJ, Boulware SD, **Mason GF**, Rothman DL, Shulman GI, Prichard JW, Shulman RG (1994) Localized ^{13}C NMR spectroscopy in the human brain of amino acid labeling from $[1\text{-}^{13}\text{C}]\text{D}$ -glucose. *J Neurochem* 63: 1377-1385
12. **Mason GF**, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, α -ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. *J Cereb Blood Flow Metab* 15: 12-25
13. **Mason GF**, Pohost GM, Hetherington HP (1995) Numerically optimized experimental design for measurement of grey/white matter metabolite T_2 in high-resolution spectroscopic images of brain. *J Magn Reson, Series B* 107: 68-73
14. Hetherington H, Kuzniecky R, Pan J, **Mason G**, Morawetz R, Harris C, Faught E, Vaughan T, Pohost G (1995) ^1H NMR spectroscopic imaging of human temporal lobe epilepsy at 4.1 Tesla. *Ann Neurol* 38: 396-404
15. Hetherington HP, Pan JW, **Mason GF**, Adams D, Vaughn MJ, Twieg DB, Pohost GM (1996) Quantitative high-resolution spectroscopic imaging of human brain *in vivo* at 4.1T using image segmentation. *Magn Reson Med* 36: 21-29
16. Pan JW, **Mason GF**, Pohost GM, Hetherington HP (1996) Spectroscopic imaging of human cerebral glutamate by J-refocused spectroscopic imaging at 4.1T. *Magn Reson Med* 36: 7-12
17. Hyder F, Chase JR, Behar KL, **Mason GF**, Siddeek M, Rothman DL, Shulman RG (1996) Increased tri-carboxylic acid cycle flux in rat brain during fore-paw stimulation detected by ^1H - ^{13}C nuclear magnetic resonance spectroscopy. *Proc Natl Acad Sci USA* 93: 7612-7617 PMID: PMC38794
18. Manor D, Rothman DL, **Mason GF**, Hyder F, Petroff OAC, Behar KL (1996) The rate of turnover of cortical GABA from $[1\text{-}^{13}\text{C}]\text{glucose}$ is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (γ -vinyl GABA). *Neurochem Res* 21: 1031-1041
19. Pan JW, **Mason GF**, Vaughan JT, Chu WJ, Zhang Y, Hetherington HP (1997) ^{13}C editing of glutamate in human brain using J-refocused coherence transfer spectroscopy at 4.1T. *Magn Reson Med* 37: 355-358
20. Sibson NR, Dhankhar A, **Mason GF**, Behar KL, Rothman DL, Shulman RG (1997) *In vivo* ^{13}C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. *Proc Natl Acad Sci USA* 94: 2699-2704 PMID: PMC20152

21. **Mason GF**, Chu WJ, Pohost GM, Hetherington HP (1997) A general approach to numerically optimized design of experiments: application to multi-slice tissue segmentation via T₁ imaging in human brain. *J Magn Reson* 126: 18-29; correction for publisher's error in volume 126, number 2
22. **Mason GF**, Harshbarger T, Hetherington HP, Pohost GM, Twieg DB (1997) A method to measure arbitrary k-space trajectories for rapid MR imaging. *Magn Reson Med* 38: 492-496
23. Hyder F, Rothman DL, **Mason GF**, Boucher RB, Behar KL, Shulman RG (1997) Oxidative glucose metabolism in rat brain during single forepaw stimulation: a spatially localized ¹H[¹³C] NMR study. *J Cereb Blood Flow Metab* 17: 1040-1047
24. Hetherington HP, Pan JW, Chu W-J, **Mason GF**, Newcomer BR (1997) Biological and clinical MRS at ultra-high field. *NMR in Biomedicine* 10: 360-371
25. Sibson NR, Dhankhar A, **Mason GF**, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. *Proc Natl Acad Sci USA* 95: 316-321
PMCID: PMC18211
26. **Mason GF**, Chu WJ, Ponder SL, Vaughan JT, Adams D, Hetherington HP (1998) Evaluation of ³¹P metabolite levels in grey matter and white matter using multi-slice tissue segmentation and spectroscopic imaging of human brain. *Magn Reson Med* 39: 346-353
27. Zhang Y, Hetherington HP, Stokely EM, **Mason GF**, Twieg DB (1998) A novel k-space trajectory measurement technique. *Magn Reson Med* 39: 999-1004
28. Chu WJ, Hetherington HP, Kuzniecky RI, Simor T, **Mason GF**, Elgavish GA (1998) Lateralization of human temporal lobe epilepsy by ³¹P NMR spectroscopic imaging at 4.1T. *Neurology* 51: 472-479
29. Sibson NR, Shen J, **Mason GF**, Rothman DL, Behar KL, Shulman RG (1998) Functional energy metabolism: *in vivo* ¹³C NMR evidence for coupling of cerebral glucose consumption and glutamatergic neuronal activity. *Dev Neurosci* 20: 321-330
30. **Mason GF**, Pan JW, Chu WJ, Zhang YT, Newcomer BD, Hetherington HP (1999) Measurement of the Tricarboxylic Acid Cycle Rate in Human Grey and White Matter *in vivo* by ¹³C Magnetic Resonance Spectroscopy at 4.1T. *J Cereb Blood Flow Metab* 19: 1179-1188
31. Sanacora G, **Mason GF**, Rothman DL, Behar KL, Petroff OAC, Berman RM, Krystal JH (1999) Preliminary evidence of reduced cortical GABA levels in depressed patients assessed using ¹H-magnetic resonance spectroscopy. *Archives of General Psychiatry* 56: 1043-1047
32. Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, **Mason GF**, Petroff OA, Shulman GI, Shulman RG, Rothman DL (1999) Determination of the rate of the glutamate/glutamine cycle in the human brain by *in vivo* ¹³C NMR. *Proc Natl Acad Sci USA* 96: 8235-8240
PMCID: PMC22218
33. Hyder F, Kennan RP, Kida I, **Mason GF**, Behar KL, Rothman D (2000) Dependence of oxygen delivery on blood flow in rat brain: a 7 Tesla nuclear magnetic resonance study. *J Cereb Blood Flow Metab* 20: 485-498
34. **Mason GF**, Lai JCK (2000) Nonlinear determination of Michaelis-Menten kinetics with model evaluation through estimation of uncertainties. *Metab Brain Disease* 15: 133-149
35. Pan JW, Stein DT, Telang F, Lee JH, Heydari S, **Mason G**, Rothman DL, Hetherington HP (2000) Spectroscopic imaging of glutamate C4 turnover in human brain. *Magn Reson Med* 44: 673-679
36. Novotny EJ, Ariyan C, **Mason G**, O'Reilly J Jr, Haddad GG, Behar KL (2001) Differential increase in cerebral cortical glucose oxidative metabolism during rat postnatal development is greater *in vivo* than *in vitro*. *Brain Research* 888: 193-202
37. Sibson NR, **Mason GF**, Shen J, Cline GW, Herskovits AZ, Wall JEM, Behar KL, Rothman DL, Shulman RG (2001) *In vivo* ¹³C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during [2-¹³C]glucose infusion. *J Neurochem* 76: 975-989
38. Goddard AW, **Mason GF**, Almai A, Rothman DL, Behar KL, Petroff OAC, Charney DS, Krystal JH (2001) Reductions in cortical GABA levels in panic disorder detected with ¹H-magnetic resonance spectroscopy. *Arch Gen Psychiatry* 58: 556-561
39. **Mason GF**, Martin DL, Martin SB, Manor D, Sibson NR, Patel A, Rothman DL, Behar KL (2001) Decrease in GABA synthesis rate in rat cortex following vigabatrin administration correlates with the decrease in GAD⁶⁷ protein. *Brain Research* 914: 81-91
40. Lebon V, Petersen KF, Cline GW, Shen J, **Mason GF**, Dufour S, Behar KL, Shulman GI, Rothman DL (2002) Astroglial contribution to brain energy metabolism in humans revealed by ¹³C NMR spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. *J Neurosci* 22: 1523-1531 (cover article)

41. Sanacora G, **Mason GF**, Rothman DL, Krystal JH (2002) Increased cortical GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. *Am J Psychiatry* 159: 663-665
42. Chu W-J, **Mason GF**, Pan JW, Hetherington HP, Liu H-G, San Pedro E, Mountz JM (2002) Regional cerebral blood flow and magnetic resonance spectroscopic imaging findings in diaschisis from stroke. *Stroke* 33: 1243-1248 (cover article)
43. Epperson NE, Haga KH, **Mason GF**, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman D, Krystal JH (2002) Cortical γ -aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a ^1H -MRS study. *Arch Gen Psych* 59: 851-858
44. **Mason GF**, Rothman DL (2002) Graded Image Segmentation of Brain Tissue in the Presence of Inhomogeneous Radio Frequency Fields. *Magn Reson Imaging* 20: 431-436
45. Sanacora G, **Mason GF**, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH (2003) Increased cortical GABA concentrations in depressed patients receiving ECT. *Am J Psychiatry* 160: 577-579
46. de Graaf RA, Brown PB, **Mason GF**, Rothman DL, Behar KL (2003) Detection of $[1,6-^{13}\text{C}]$ -glucose metabolism in rat brain by in vivo ^1H - $[^{13}\text{C}]$ -NMR spectroscopy. *Magn Reson Med* 49: 37-46
47. **Mason GF**, Petersen KF, de Graaf RA, Kanamatsu T, Otsuki T, Shulman GI, Rothman DL (2003) A Comparison of ^{13}C NMR Measurements of the Rates of Glutamine Synthesis and the Tricarboxylic Acid Cycle During Oral and Intravenous Administration of $[1-^{13}\text{C}]$ Glucose. *Brain Res Protocols* 10: 181-190
48. Kugaya A, Sanacora G, Verhoeff NPLG, Fujita M, **Mason GF**, Seneca NM, Bozkurt, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB (2003) Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors *Biol Psychiatry* 54: 792-799
49. Kugaya A, Sanacora G, Verhoeff NP, Fujita M, **Mason GF**, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB (2003) Cerebral benzodiazepine receptors in depressed patients measured with $[^{123}\text{I}]$ iomazenil SPECT. *Biol Psychiatry* 54: 792-799
50. Patel AB, de Graaf RA, **Mason GF** Rothman DL, Shulman RG, Behar KL (2003) Coupling of glutamatergic neurotransmission and neuronal glucose oxidation over the entire range of cerebral cortex activity. *Ann New York Acad Sci* 1003: 452-453
51. Goddard AW, **Mason GF**, Appel M, Rothman DL, Behar KL, Krystal JH (2004) Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder. *Neuropsychopharmacology* 29: 639-640
52. Sanacora G, Blumberg H, Rothman DL, Krystal JH, **Mason GF** (2004) Subtype-specific alterations of γ -aminobutyric acid and glutamate in patients with major depression. *Arch Gen Psych* 61: 705-713 (cover article)
53. Patel AB, de Graaf RA, **Mason GF**, Kanamatsu T, Rothman DL, Shulman RG, Behar KL (2004) Glutamatergic neurotransmission and neuronal glucose oxidation are coupled during intense neuronal activation. *J Cereb Blood Flow Metab* 24: 972-985
54. de Graaf RA, **Mason GF**, Patel AB, Rothman DL, Behar KL (2004) Regional glucose metabolism and glutamatergic neurotransmission in rat brain *in vivo*. *Proc Natl Acad Sci USA* 101: 12700-12705
55. Goddard AW, **Mason GF**, Appel M, Rothman DL, Gueorguieva R, Behar KL, Krystal JH (2004) Reduced cortical GABA neuronal response to benzodiazepine administration in panic disorder. *Am J Psychiatry* 161: 2186-2193 (cover article)
56. Epperson CN, O'Malley S, Czarkowski K, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, **Mason GF** (2004) Sex, GABA, and nicotine: the impact of smoking on cortical gamma-aminobutyric acid levels across the menstrual cycle as measured with ^1H -MRS. *Biol Psychiatry* 57: 44-48
57. Patel AB, de Graaf RA, **Mason GF**, Rothman DL, Shulman RG, Behar KL (2005) The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex *in vivo*. *Proc Natl Acad Sci USA* 102: 5588-5593 PMID: PMC556230
58. **Mason GF**, Petrakis IL, de Graaf RA, Appel M, Gueorguieva R, Guidone E, Coric V, Epperson CN, Rothman DL, Krystal JH (2006) Cortical GABA Levels and the Recovery from Alcohol Dependence: Preliminary Evidence of Modification by Cigarette Smoking. *Biol Psychiatry* 59: 85-93
59. Sanacora G, Fenton L, Fasula M, Rothman DL, Krystal JH, **Mason GF** (2006) Cortical GABA Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy. *Biol Psych* 59: 284-286
60. **Mason GF**, Petersen KF, Lebon V, Rothman DL, Shulman GI (2006) Increased Brain Monocarboxylic Acid Transport and Utilization in Type 1 Diabetes. *Diabetes* 55: 929-934

61. Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH, Rothman DL, **Mason GF** (2006) Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. *Psychopharmacol* 186: 425-433
62. Amin Z, **Mason GF**, Cavus I, Rothman DL, Epperson CN (2006) The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. *Pharmacol dBiochem Behav* 84: 635-643
63. **Mason GF**, Petersen KF, de Graaf RA, Shulman GI, Rothman DL (2007) Measurements of the anaplerotic rate in the human cerebral cortex using ¹³C MRS and [1-¹³C] and [2-¹³C]glucose. *J Neurochem* 100: 73-86 PMID: PMC515118
64. Chowdhury GMI, Patel AB, **Mason GF**, Rothman DL, Behar KL (2007) Glutamatergic and GABAergic Neurotransmitter Cycling and Energy Metabolism in Rat Cerebral Cortex During Postnatal Development. *J Cereb Blood Flow Metab* 27: 1895-1907 PMID 17440492
65. Befroy D, Dufour S, **Mason GF**, de Graaf RA, Petersen KF, Rothman DL, Shulman GI (2008) Impaired Mitochondrial Oxidation in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Patients *Diabetes* (in 56: 1376-1381
66. Befroy DE, Petersen KF, Dufour S, **Mason GF**, Rothman DL, and Shulman GI (2008) Increased substrate oxidation and mitochondrial uncoupling in skeletal muscle of endurance-trained individuals. *Proc Natl Acad Sci USA* 28; 105(43): 16701–16706, PMID PMC2570428
67. Jiang L, Herzog RI, **Mason GF**, de Graaf RA, Rothman DL, Sherwin RS, Behar KL (2009) Recurrent Antecedent Hypoglycemia Alters Neuronal Oxidative Metabolism in Vivo. *Diabetes* 58: 1266-1274 PMID PMC2682668
68. Boumezbeur F, **Mason GF**, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, Petersen KF (2010) Alterations in brain mitochondrial metabolism associated with aging in humans. *J Cereb Blood Flow Metab* 30: 211-221 PMID 19794401
69. van Eijsden P, Behar KL, **Mason GF**, Braun KPJ, de Graaf RA (2010) *In Vivo* Neurochemical Profiling of Rat Brain by ¹H-[¹³C] MRS: Cerebral Energetics and Glutamatergic/GABAergic Neurotransmission. *J Neurochem* 112: 24-33, PMID: PMC2843425
70. Patel AB, de Graaf RA, Rothman DL, Behar KL, **Mason GF** (2010) Evaluation of cerebral acetate transport and utilization rates in the anesthetized rat *in vivo* using ¹H-[¹³C]NMR and [2-¹³C]acetate. *J Cereb Blood Flow Metab* 30: 1200-1213, PMID: PMC2879471
71. Wang J, Jiang L, Jiang F, Ma X, Chowdhury GMI, **Mason G** (2010) Regional metabolite levels and turnover in the awake rat brain under the influence of nicotine. *J Neurochem* 113: 1447-1458, PMID: PMC2903655
72. Boumezbeur F, Petersen K, Cline G, **Mason GF**, Behar K, Shulman G, Rothman D (2010) The contribution of blood lactate to brain energy metabolism in humans measured by dynamic ¹³C nuclear magnetic resonance spectroscopy. *J Neurosci* 30(42):13983–13991
73. Palejev D, Hwang W, Landi N, Eastman M, Frost SJ, Fulbright RK, Kidd JR, Kidd KK, **Mason GF**, Mencl WE, Yrigollenn C, Pugh KR, Grigorenko EL (2011) An Application of the Elastic Net for an Endophenotype Analysis. *Behav Genet* 41: 120-124
74. Valentine GW, **Mason GF**, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. *Psychiatry Res* 191: 122-127
75. Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, **Mason GF** (2012) Intravenous ethanol infusion decreases human cortical GABA and NAA as measured with ¹H-MRS at 4T. *Biol Psychiatry* 71: 239-246
76. Morgan PT, Pace-Schott EF, **Mason GF**, Forselius E, Fasula M, Valentine GW, Sanacora G (2012) Cortical GABA levels in primary insomnia. *Sleep* 35: 807-14
77. Jiang L, **Mason G**, Rothman D, de Graaf R, Behar K (2011) Cortical substrate oxidation during hyperketonemia in the fasted anesthetized rat *in vivo*. *J Cereb Blood Flow Metab* 31: 2313-2323
78. Wang J, Jiang L, Du H, **Mason GF** (2012) An ethanol vapor chamber system for small animals. *J Neurosci Methods* 208: 79-85
79. Jiang L, Gulanski BI, de Feyter, Weinzimer S, Pittman B, Guidone E, Koretski J, Harman S, Petrakis IL, Krystal JH, **Mason GF** (2013) Increased Brain Uptake and Oxidation of Acetate in Heavy Drinkers. *J Clin Inv* 123: 1605-1614

80. Herzog RI, Jiang L, Herman P, Zhao C, Sanganahalli BG, **Mason GF**, Hyder F, Rothman DL, Sherwin RS, Behar KL (2013) Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. *J Clin Inv* 123: 1988–1998
81. Wang J, Du H, Jiang L, Ma X, de Graaf R, Behar K, **Mason GF** (2013) Oxidation and Effects of Ethanol in the Rat Brain after Chronic Ethanol Exposure. *Proc Natl Acad Sci USA* 110: 14444-14449
82. Solecki W, Wickham R, Behrens S, Wang J, Zwerling B, **Mason GF**, Addy NA (2013) Differential role of ventral tegmental area acetylcholine and N-Methyl-D-Aspartate receptors in cocaine-seeking. *Neuropharmacol* 75: 9-18
83. Wang J, Du H, Ma X, Castracane L, Li T-K, Behar KL, **Mason GF** (2013) Metabolic Products of [2-¹³C]Ethanol in the Awake Rat Brain. *J Neurochem* 127: 353-364
84. De Feyter H, **Mason GF**, Shulman GI, Rothman DL, Falk Petersen K (2013) Increased Lactate Oxidation during Hypoglycemia in Type 1 Diabetic Individuals. *Diabetes* 62: 3075-3080
85. Gulanski BI, De Feyter HM, Page KA, Belfort de Aguiar R, **Mason GF**, Rothman DL, Sherwin RS (2013) Increased Brain Transport and Metabolism of Acetate in Hypoglycemia Unawareness. *J Clin Endocrin Metab* 98: 3811-3820
86. Pugh KR, Frost SJ, Rothman DL, Hoefft F, Del Tufo SN, Mason GF, Molfese PJ, Mencl WE, Grigorenko EL, Landi N, Preston JL, Jacobsen L, Seidenberg MS, Fulbright RK (2014) Glutamate and choline levels predict individual differences in reading ability in emergent readers. *J Neurosci* 34: 4082-4089
87. Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, **Mason GF**, Sanacora G (2014) Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder. *Psychotherapy & Psychosomatics* 83:298-307
88. Bagga F, Behar KL, **Mason GF**, De Feyter H, Rothman DL, Patel AB (2014) Characterization of cerebral glutamine uptake from blood in the anesthetized mouse with implications for metabolic modeling of ¹³C NMR data. *J Cereb Blood Flow Metab* 34:1666-1672
89. Abdallah CG, Jiang L, De Feyter HM, Fasula MK, Krystal JH, Rothman DL, **Mason GF**, Sanacora G (2014) Glutamate Metabolism in Major Depressive Disorder. *Amer J Psychiatry* 171:1320-1327
90. Alves TC, Pongratz RL, Zhao X, Yarborough O, Sereda S, Shirihai O, Cline GW, **Mason GF**, Kibbey RG (2015) Integrated, step-wise, mass-isotopomeric flux analysis of the TCA Cycle. *Cell Metab* 22.5: 936-947
91. Prinsen H, de Graaf RA, **Mason GF**, Pelletier D, Juchem C (2017) Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. *J Magn Reson Imag* 45: 197-198
92. Hwang JJ, Jiang L, Hamza M, Dai F, Belfort-DeAguiar R, Cline G, Rothman DL, **Mason G**, Sherwin RS (2017) The human brain produces fructose from glucose. *JCI Insight* 2: e90508
93. Abdallah CG, Hannestad J, **Mason GF**, Holmes S, Della Goia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, Esterlis I (2017) Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. *Biol Psych Cogn Neurosci Neuroimag* 2: 449-456
94. Hwang JJ, Jiang L, Hamza M, Sanchez Rangel E, Dai F, Belfort-DeAguiar R, Parikh L, Koo BB, Rothman DL, **Mason G**, Sherwin RS (2017) Blunted rise in brain glucose levels during hyperglycemia in adults with obesity and T2DM *JCI Insight* 2: e9591
95. De Feyter HM, Herzog RI, Steensma BR, Klomp DWJ, Brown PB, **Mason GF**, Rothman DL, Graaf RA (2018) Selective Proton-Observed, Carbon-Edited (selPOCE) MRS method for measurement of glutamate and glutamine ¹³C-labeling in the human frontal cortex. *Magn Reson Med* 80: 11-20
96. Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, **Mason G**, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo T-H, Grinband J, Lieberman JA (2018) Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. *JAMA Psychiatry* 75: 11-19
97. Abdallah CG, Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, **Mason GF** (2018) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. *Neuropsychopharmacol* 43: 2154–2160
98. Del Tufo SN, Frost SJ, Hoefft F, Cutting LE, Molfese PJ, **Mason GF**, Rothman DL, Fulbright RK, Pugh KR (2018) Neurochemistry predicts convergence of written and spoken Language: A proton magnetic resonance spectroscopy study of cross-modal language integration. *Front Neurosci* 9: 1507.

99. Hwang JJ, Jiang L, Rangel ES, Fan X, Ding Y, Lam W, Leventhal J, Dai F, Rothman DL, **Mason GF**, Sherwin RS (2019) Glycemic variability and brain glucose levels in type 1 diabetes. *Diabetes* 68: 163-171.
100. Nozaki Y, Petersen MC, Zhang D, Vatner DF, Perry RJ, Abulzi A, Haedersdal S, Zhang X-M, Butrico GM, Samuel VT, **Mason GF**, Cline GW, Petersen KF, Rothman DL, Shulman GI (2020) Metabolic Control Analysis of Hepatic Glycogen Synthesis *In Vivo*. *Proc Natl Acad Sci USA* 117: 8166-8176
101. Mishra PK, Adusumilli M, Deolal P, **Mason GF**, Kumar A, Patel AB (2020) Impaired Neuronal and Astroglial Metabolic Activity in Chronic Unpredictable Mild Stress Model of Depression: Reversal of Behavioral and Metabolic deficit with Lanicemine. *Neurochem Intl* 137: 104750
102. Averill LA, Abdallah CG, Fenton LR, Fasula MK, Jiang L, Rothman DL, **Mason GF**, Sanacora G (2020) Early Life Stress and Glutamate Neurotransmission in Major Depressive Disorder. *Eur Neuropsychopharmacol* 35: 71-80
103. Song JD, Alves TC, Befroy DE, Perry RJ, **Mason GF**, Zhang XM, Munk A, Zhang Y, Zhang D, Cline GW, Rothman DL. Dissociation of muscle insulin resistance from alterations in mitochondrial substrate preference. *Cell Metabolism* 32: 726-35.
104. Nozaki Y, Petersen MC, Zhang D, Vatner DF, Perry RJ, Abulizi A, Haedersdal S, Zhang XM, Butrico GM, Samuel VT, Mason GF (2020) Metabolic control analysis of hepatic glycogen synthesis in vivo. *Proc Natl Acad Sci USA* 117: 8166-8176.
105. Abulizi A, Cardone RL, Stark R, Lewandowski SL, Zhao X, Hillion J, Ma L, Sehgal R, Alves TC, Thomas C, Kung C, Wang B, Siebel S, Andrews ZB, Rinehart J, **Mason G**, Merrins MJ, Kibbey RC (2020) Multi-tissue acceleration of the mitochondrial phosphoenolpyruvate cycle improves whole-body metabolic health. *Cell Metabolism* (Cover article) 32:751-766
106. Bornebusch AB, **Mason GF**, Tonetto S, Damsgaard J, Gjedde A, Fink-Jensen A, Thomsen M (2021) Effects of ketogenic diet and ketone monoester supplement on acute alcohol withdrawal symptoms in male mice. *Psychopharmacology* 238:833–844
107. Miller CO, Gantert LT, Previs SF, Chen Y, Anderson KD, Thomas JM, Sanacora S, Uslaner JM, Rothman DL, **Mason GF** (2022) A novel biomarker of neuronal glutamate metabolism in non-human primate using localized 1H MRS: Development and effects of BNC375, an $\alpha 7$ nicotinic acetylcholine receptor positive allosteric modulator. *Biol Psych: Cogn Neurosci Neuroimag*
<https://doi.org/10.1016/j.bpsc.2020.09.014>
108. Sanchez-Rangel E, Gunawan F, Jiang L, Savoye M, Dai F, Coppoli A, Rothman DL, **Mason GF**, Hwang JJ (2022) Reversibility of Brain Glucose Kinetics in Type 2 Diabetes Mellitus. *Diabetologia* 65, 895–905.
109. McNair LM, **Mason GF**, Chowdhury GMI, Jiang L, Ma X, Rothman DL, Waagepetersen HS, Behar KL (2022) Rates of pyruvate carboxylase, glutamate and GABA neurotransmitter cycling, and glucose oxidation in multiple brain regions of the awake rat using a combination of [2- 13 C]/[1- 13 C]-glucose infusion and 1 H- 13 C]NMR *ex vivo*. *J Cereb Blood Flow Metab* 42: 1507–1523
110. Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter H, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, **Mason GF**, Abdallah CG (2022) Prefrontal glutamate neurotransmission in PTSD: A novel approach to estimate synaptic strength in vivo in humans. *Chronic Stress* 6: 24705470221092734
111. Kumaragamage C, Coppoli A, Brown PB, McIntyre S, Nixon TW, De Feyter HM, **Mason GF**, de Graaf RA (2022) Short symmetric and highly selective asymmetric first and second order gradient modulated offset independent adiabaticity (GOIA) pulses for applications in clinical MRS and MRSI. *J Magn Reson* 341: 107247
112. Marinkovic K, Myers ABA, Arienzo D, Serenoa MI, **Mason GF** (2022) Cortical GABA levels are reduced in young adult binge drinkers: Association with recent consumption and sex. *NeuroImage: Clinical* 35: 103091
113. Hubbard BT, LaMoia TE, Goedeke L, Gaspar RC, Galsgaard KD, Kahn M, **Mason GF**, Shulman GI (2023) Q-Flux: A method to assess hepatic mitochondrial succinate dehydrogenase, methylmalonyl-CoA mutase, and glutaminase fluxes in vivo. *Cell Metabolism* 35: 212-226
114. Chowdhury GMI, Behar KL, **Mason GF**, Rothman DL, de Graaf RA (2024) Measurement of Neuroenergetics and Neurotransmission in the Rat Olfactory Bulb by 1H and 1 H- 13 C] NMR Spectroscopy. *NMR Biomed* 37: e4957
115. Tamman AJF, Jiang L, Averill CL, **Mason GF**, Averill LA, Abdallah CG (2023) Biological embedding of early trauma: the role of increased prefrontal synaptic strength. *Eur J Psychotraumatology*
<https://doi.org/10.1080/20008066.2023.2246338>

116. Marinkovic K, White DR, Myers AA, Parker KS, Arienzo D, **Mason GF** (2023) Cortical GABA Levels are Reduced in Post-acute COVID-19 Syndrome. *Brain Sci* 13: 1666
117. Gunawan F, Matson BC, Coppoli A, Jiang L, Ding Y, Perry R, Sanchez-Rangel E, Belfort DeAguiar R, Behar KL, Rothman DL, **Mason GF**, Hwang JJ (2024) Deficits in brain glucose transport amongst younger adults with obesity. *Obesity* 32: 1329-1338
118. Jacobs SM, Prompers JJ, van der Kemp WJM, van der Velden TA, Gosselink WJM, Melià EF, Hoogduin JM, **Mason GF**, de Graaf RA, van der Kolk AG, Alborahal C, Klomp DWJ, Wiegers EC (2024) Indirect ^1H - ^{13}C] MRS of the brain at 7T using a ^{13}C birdcage coil and 8 transmit-receive ^1H antennas with a 32-channel ^1H receive array. *NMR Biomed* 37:e5195
119. Klausen MK, Kuzey T, Niemann Pedersen J, Keller Justesen S, Rasmussen L, Knorr UB, **Mason G**, Ekstrøm CT, Holst JJ, Koob G, Benveniste H, Volkow ND, Knudsen GM, Vilbøll T, Fink-Jensen A (2025) Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (The SEMALCO trial) *Brit Med J Open* 15: e086454

REVIEW ARTICLES and COMMENTS

1. Shulman RG, Behar KL, Rothman DL, **Mason GF** (1992) NMR studies of cerebral metabolism. *Imaging in Alcohol Research, Research Monograph* (Zakhari S, Witt E, eds) Volume 21: 195-200 DHHS Publication Number (ADM) 92-1890, Rockville, MD
2. **Mason GF**, Lai JCK, Behar KL (1996) ^{13}C and Nuclear Magnetic Resonance: unique tools for the study of brain metabolism. *Metab Brain Disease* 11: 283-313
3. Behar KL, Sibson N, Rothman DL, Hyder F, Shen J, Manor D, **Mason GF**, Shulman RG (1999) NMR studies of cerebral glutamate/glutamine cycling and GABA synthesis in vivo. *Proc Carbon-13 Applications* 8: 44-52
4. Sanacora G, **Mason GF**, Krystal JH (2000) Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. *Critical Rev Neurobiol* 14: 23-45
5. **Mason GF**, Behar KL, Krystal JK, Rothman DL (2001) Aplicações da ressonância magnética para medidas espectroscópicas da neurotransmissão. *Revista Brasileira da Psiquiatria* 23 (Suppl. 1): 6-10
6. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, **Mason GF** (2002) Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol Psychiatry* 7: S71-80
7. Sanacora G, Rothman DL, **Mason G**, Krystal JH (2003) Clinical studies implementing glutamate neurotransmission in mood disorders. *Ann New York Acad Sci* 1003: 292-308
8. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, **Mason GF** (2002) Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol Psychiatry* 7: S71-80
9. Krystal JH, Petrakis IL, **Mason G**, D'Souza DC (2003) NMDA glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. *Pharmacol Ther* 99: 79-94
10. **Mason GF** (2003) Magnetic resonance spectroscopy for studies of neurotransmission in vivo. *Psychopharm Bull* 37: 26-40
11. de Graaf RA, **Mason GF**, Patel AB, Behar KL, Rothman DL (2003) In vivo ^1H - ^{13}C] NMR spectroscopy of cerebral metabolism. *NMR Biomed* 16: 339-357
12. **Mason GF**, Rothman DL (2004) Basic Principles of Metabolic Modeling of NMR ^{13}C isotopic turnover to Determine Rates of Brain Metabolism *In Vivo*. *Metabolic Engineering* 6: 75-84 (cover)
13. **Mason GF**, Bendszus M, Meyerhoff DJ, Hetherington HP, Schweinsburg S, Ross BD, Taylor MJ, Krystal JH (2005) Magnetic Resonance Spectroscopic Studies of Alcoholism. *Alc Clin Exp Res* 29: 150-158
14. Krystal JH, Staley J, **Mason G**, Petrakis IL, Kaufman J, Harris RA, Gelernter JE, Lappalainen J (2006) GABA_A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. *Arch Gen Psychiatry* 63: 957-968
15. **Mason GF**, Krystal JH (2006) MR Spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. *NMR Biomed* 19: 690-701
16. **Mason GF** (2006) Get sober, stay sober. *Brain* 130: 8-9
17. Cosgrove KP, Esterlis I, **Mason GF**, Bois F, O'Malley SS, Krystal JH (2011) Neuroimaging insights into the role of cortical GABA systems in the interplay of nicotine and alcohol dependence. *Neuropharmacology* 60: 1318-1325

18. Rothman DL, de Feyter HM, de Graaf RA, **Mason GF**, Behar KL (2011) ^{13}C MRS studies of neuroenergetics and neurotransmitter cycling in humans. *NMR Biomed* 24: 943-957
19. Niciu MJ, **Mason GF** (2014) Neuroimaging in Alcohol and Drug Dependence. *Current Behavioral Neuroscience Reports* 1: 45-54
20. Hillmer AT, **Mason GF**, Fucito LM, O'Malley SS, Cosgrove KP (2015) How imaging glutamate, γ -aminobutyric acid, and dopamine can inform the clinical treatment of alcohol dependence and withdrawal. *Alcohol Clin Exp Res* 39: 2268-2282
21. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, **Mason GF**, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg, AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta J-K (2016) Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. *Biol Psychiatry* 80: 84-86
22. Woodcock EA, Hillmer AT, Mason GF, Cosgrove KP (2019) Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review. *Mol Neuropsychiatry* 5: 125-146
23. Rothman DL, de Graaf R, Hyder F, **Mason GF**, Behar KL, de Feyter H (2019) *In vivo* ^{13}C and ^1H - ^{13}C MRS studies of neuroenergetics and neurotransmitter cycling, applications to neurological and psychiatric disease and brain cancer. *NMR Biomed* 32: e4172
24. **Mason GF**, Krystal JH (2020) Mapping Lithium in the Brain: New 3-Dimensional Methodology Reveals Regional Distribution in Euthymic Patients With Bipolar Disorder. *Biol Psychiatry* 88: 367-368
25. Mahajan A, **Mason GF** (2021) A Sobering Addition to the New Literature on COVID-19 and the Brain. *J Clin Inv* 131: e148376
26. Abdallah C, **Mason GF** (2022) Novel Approaches to Estimate Prefrontal Synaptic Strength In Vivo In Humans: Of Relevance to Depression, Schizophrenia and Ketamine. *Neuropsychopharmacology Reviews* 47: 399-400

BOOK CHAPTERS

1. Mountz JM, Deutsch G, Inampudi C, Liu H-G, Hetherington HP, Pan JW, **Mason GF**, Mennemeier M, Richards JS, Pohost GM (1995) Current status of SPECT brain imaging in the evaluation of cerebrovascular disease. *Nuclear Medicine in a Changing World*, (Serafini AN, ed.) Southeastern Chapter, The Society of Nuclear Medicine publisher. Chapter 7, pp. 1-9
2. Mountz JM, Deutsch G, Hetherington HP, Inampudi C, San Pedro E, Liu H-G, Pan JW, **Mason GF**, Mennemeier M, Richard S, Pohost GM (1997) Applications of rCBF brain SPECT and NMR imaging in the evaluation of stroke: implications in rehabilitation prognosis. In *Brain SPECT in Neurology and Psychiatry*. Deyn PP, Dierckx RA, Alavi A, Pickut BA (ed.) John Libbey & Company Ltd., London, UK, pages 335-346
3. **Mason GF** (1998) Applications of ^{13}C -labeling to studies of brain metabolism *in vivo*. *Biological Magnetic Resonance* (Berliner LJ, Robitaille P-M, ed.) Vol. 15, pp. 181-214
4. Krystal JH, Petrakis IL, D'Souza DC, **Mason G**, Trevisan L (2001) Alcohol and Glutamate Neurotransmission in Humans: Implications for Reward, Dependence, and Treatment. In *Glutamate and Addiction*. Human Press, Totowa, New Jersey. pp. 389-397
5. Rothman DL, Hyder F, Sibson N, Behar KL, **Mason GF**, Shen J, Petroff OAC, Shulman RG (2002) In vivo magnetic resonance spectroscopy studies of the glutamate and GABA neurotransmitter cycles and functional neuroenergetics. *American College of Neuropsychopharmacology 5th Generation CD-ROM* pp. 315-342
6. Sanacora G, **Mason GF**, Khan SA (2003) GABAergic abnormalities in mood disorders: magnetic resonance spectroscopy investigation. *Brain Imaging in Affective Disorders*, Marcel Dekker, New York; Soares J, ed., pp.
7. **Mason GF** (2004) Metabolic modeling analysis of brain metabolism, in *Brain Energetics and Neuronal Activity: Applications to fMRI and Medicine*, John Wiley & Sons, West Sussex, UK, pp. 31-72
8. **Mason GF** (2004) The role of altered energetics of neurotransmitter systems in psychiatric disease, in *Brain Energetics and Neuronal Activity: Applications to fMRI and Medicine*, John Wiley & Sons, West Sussex, UK, pp. 239-256

9. Epperson CN, Amin Z, **Mason GF** (2007) Pathophysiology II: neuroimaging, GABA and the menstrual cycle. In *The Premenstrual Syndromes: PMS and PMDD*, eds. O'Brien PM, Rapkin AJ, Schmidt PJ. Informa Healthcare, London, England, pp 99-10
10. **Mason GF**, Krystal JH, Sanacora G (2009) Nuclear magnetic resonance imaging and spectroscopy: basic principles and recent findings in neuropsychiatric disorders. In *Comprehensive Textbook of Psychiatry*, Lippincott Williams and Wilkins (Sadock BJ, Sadock VA, Ruiz P, eds.)
11. **Mason GF** (2009) Imaging Techniques: Visualizing the Living Brain. In *Gale Encyclopedia of Drugs, Alcohol, and Addictive Behavior, 3rd Edition*, (Kranzler HR, Korsmeyer P, eds.)
12. Schweinsburg B, Schweinsburg A, **Mason GF** (2010) Substance Abuse – Neurochemical. In *Understanding Neuropsychiatric Disorders: Insights from Neuroimaging*, Shenton M, Turetsky B, eds., pp. 446-462
13. **Mason GF**, Jiang L, Behar KL (2014) Compartmental Analysis of Metabolism by ¹³C Magnetic Resonance Spectroscopy. In *NeuroMethods: Brain Energy Metabolism*, Waagepetersen H, Hirrlinger J, eds., Vol. 90, Chapter 13, pp. 293-339.
14. **Mason GF**, Krystal JH, Sanacora G (2017) Nuclear magnetic resonance imaging and spectroscopy: basic principles and recent findings in neuropsychiatric disorders. In *Comprehensive Textbook of Psychiatry*, Lippincott Williams and Wilkins (Sadock BJ, Sadock VA, Ruiz P, eds.)
15. Del Tufo SN, Frost SJ, Hoeft F, Cutting LE, Molfese PJ, **Mason GF**, Rothman DL, Fulbright RK, Pugh KR (2018) Neurochemistry predicts convergence of written and spoken language: a proton magnetic resonance spectroscopy study of cross-modal language integration. *Frontiers in Psychology* **4** (9): 89-105
16. Rothman DL, de Feyter HM, Mason GF, de Graaf RA, Hyder F, Behar KL (2021) *Encyclopedia of Biological Chemistry, 3rd Edition*. Methods | ¹³C MRS Measurements of in Vivo Rates of the Glutamate/Glutamine and GABA/Glutamine Neurotransmitter Cycles, p. 688-700
17. **Mason GF**, Krystal JH, Sanacora G (2024) Nuclear magnetic resonance imaging and spectroscopy: basic principles and recent findings in neuropsychiatric disorders. In *Comprehensive Textbook of Psychiatry*, Wolters Kluwer (Sadock BJ, Sadock VA, Ruiz P, eds.)

INVITED ORAL PRESENTATIONS

1. **Mason GF** (1992) ¹³C NMR studies of brain metabolism *in vivo*. Center for Nuclear Imaging Research, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, Sept. 13
2. **Mason GF** (1995) Assessment of models and determination of metabolic rates with models for ¹³C-labeling at 2.1 and 4.1T. *Proc Soc Magn Reson 3rd Annual Mtg* (August: Nice France)
3. **Mason GF** (1996) Understanding brain metabolism with ¹³C labeling. Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, March 26
4. **Mason GF** (1997) Quantitative Magnetic Resonance Imaging and Spectroscopic Studies at 4.1T. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, January 13
5. **Mason GF** (1997) Quantitative Magnetic Resonance Imaging and Spectroscopy at 4.1 T. Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY, January 22
6. **Mason GF** (1997) ¹³C isotopic labeling studies of the brain. Course on “Cutting Edge Spectroscopy”, *Intern Soc Magn Reson Med, 5th Mtg*, Vancouver, Canada, April 14
7. **Mason GF** (1998) [¹³C]-MR Spectroscopy of Glutamate, Glutamine, and GABA Turnover: Implications for Psychiatry, *Society of Biological Psychiatry*, Toronto, Canada, May 28
8. **Mason GF**, Sibson N, Hyder F, Shen J, Behar K, Krystal J, Shulman R, Rothman D (1998) The relationship of amino acid neurotransmission, neuronal metabolism, and cerebral blood flow. *American College of Neuropsychopharmacology*, December 15, Croabas, Puerto Rico
9. **Mason GF** (2001) Methods of MRS and Neuropsychiatric Applications. In: Issues of fMRI in Psychiatry. *Brown University*, Hunter Psychology Laboratory, October 24, 2001
10. **Mason GF** (2001) Methods of ¹³C MRS Detection and Metabolic Modeling. *American College of Neuropsychopharmacology*, December, Kona, Hawaii
11. **Mason GF** (2002) MRS Methodology and Applications to Major Depressive Disorder. January 17, Indiana University and Purdue University, Department of Psychiatry
12. **Mason GF** (2003) Neuronal-Glial Interactions and Cellular Energetics. July 10th, Toronto, Canada, *International Society of Magnetic Resonance in Medicine*, Teaching Day
13. **Mason GF** (2003) Substrate Transport and Utilization by the Brain. July 12, Toronto, Canada, *International Society of Magnetic Resonance in Medicine, Dynamic Spectroscopy Study Group*

14. **Mason GF** (2004) Magnetic Resonance Spectroscopy: Methodology and Studies of Cortical GABA and Glutamate in Alcoholism and Nicotine Dependence. January 13, University of Connecticut Healthcare Center, Farmington, Connecticut, *General Clinical Research Center*
15. **Mason GF** (2004) Methodology of Magnetic Resonance Spectroscopy. January 17, New Haven, Connecticut, *International Conference on Applications of Neuroimaging to Alcoholism*
16. **Mason GF** (2004) Dynamic Measurements of Cortical GABA. May 15, Kyoto, Japan. *Psychiatry Study Group of the International Society of Magnetic Resonance in Medicine*
17. **Mason GF**, Behar KL, de Graaf RA, Patel AB, Sibson N, Shulman RG, Rothman DL (2004) Measuring cerebral energy and neurotransmitter metabolism in vivo with nuclear magnetic resonance. October 13. *Annual Meeting of the Biomedical Engineering Society*, abstract #421
18. **Mason GF** (2005) Psychiatric Applications of Magnetic Resonance Spectroscopy, May 7, Miami, Florida, *International Society of Magnetic Resonance in Medicine*
19. **Mason GF** (2005) MR Spectroscopic Studies of GABA and Glutamate in Psychiatry, August 22, Innsbruck, Austria, *International Society for Neurochemistry*, abstract #W3.C, p. 24 of the proceedings
20. **Mason GF** (2005) Metabolic Modeling and Experiment Design to Study Brain Metabolism. September 7, Cleveland, Ohio, *Case Western Reserve University Center for Modeling Integrated Metabolic Systems*
21. **Mason GF** (2005) GABA and Glutamate: Use in Neuropsychiatric Disorders, October 17, Banff, Alberta, Canada, *Neuropsychiatric Applications of MRS: Joint Educational Workshop of the Psychiatric MR and Dynamic Spectroscopy Study Groups*
22. **Mason GF** (2005) Studies of Neurotransmitters in Neuropsychiatric Disorders, November 4, Nashville, Tennessee, *Vanderbilt Brain Institute*
23. **Mason GF** (2006) MRS Studies of Neurotransmitter Metabolism, January 6, Edmonton, Alberta, Canada, *University of Alberta*
24. **Mason GF** (2007) Measurements of metabolic flow with multiple substrates, March 24, Louisville, Kentucky, University of Kentucky, *Second International Symposium on Metabolomics*
25. **Mason GF** (2007) Studies of brain glutamate and GABA with strategically selected labeling of isotopic substrates. Grand Rounds at University of Mississippi Medical Center, September 25, Jackson, Mississippi
26. **Mason GF** (2007) Effects of acute nicotine administration of brain GABA. *American College of Neuropsychopharmacology, Boca Raton, Florida*
27. **Mason GF** (2008) Influences of acute nicotine and ethanol administration on brain metabolism. *Second International Conference on Applications of Neuroimaging to Alcoholism*, January 19, New Haven, Connecticut
28. **Mason GF** (2008) Espectroscopia Cerebral por Ressonância Magnética: Métodos, Limitações e Perspectivas, August 29, Departamento da Radiologia Diagnóstica por Imagem, Universidade Federal de São Paulo, SP, Brazil
29. **Mason GF** (2008) Espectroscopia nos Transtornos Psiquiátricos, August 29, Departamento da Psiquiatria, Universidade Federal de São Paulo, SP, Brazil
30. **Mason GF** (2008) Emprego da espectroscopia de ressonância magnética nuclear para determinação do GABA, glutamato e outros metabólitos no sistema nervoso central, September 2, *Congresso IBRO/LARC de Neurociências da América Latina, Caribe, e Península Ibérica*, Búzios, RJ, Brazil
31. **Mason GF** (2008) Variações do GABA e glutamato no córtex occipital de pacientes não alcoolistas durante infusão contínua de etanol, September 3, *Congresso IBRO/LARC de Neurociências da América Latina, Caribe, e Península Ibérica*, Búzios, RJ, Brazil.
32. **Mason GF** (2008) MRS Methodology for Studies of Alcoholism. *Joint INSERM-NIAAA Meeting*, October 3, Paris, France
33. **Mason GF** (2008) Basics of Cerebral Energetic and Amino Acid Neurotransmitter Metabolism, *ISMRM Workshop on MRS and Neurotransmitter Function in Neuropsychiatric Disorders*, in basic education session, November 7, Québec City, Québec.
34. **Mason GF** (2008) GABA and Glutamate in Neuropsychiatric Disorders, *ISMRM Workshop on MRS and Neurotransmitter Function in Neuropsychiatric Disorders*, plenary lecture, November 8, Québec City, Québec.
35. **Mason GF** (2008) Acute Administration of Nicotine and Ethanol: Effects on Neurochemistry. *ISMRM Workshop on MRS and Neurotransmitter Function in Neuropsychiatric Disorders*, substance abuse session, November 10, Québec City, Québec.

36. **Mason GF** (2009) Magnetic Resonance Spectroscopy Applied to Study Neurochemistry. May 3, Lanzhou University, Lanzhou, China.
37. **Mason GF** (2009) Neurochemical Effects of Acute Nicotine and Alcohol. May 4, Lanzhou University, Lanzhou, China
38. **Mason GF** (2009) Magnetic Resonance Spectroscopy and Neurotransmitters in Psychiatric Disorders. May 6, Wuhan, China
39. **Mason GF** (2009) Métodos de espectroscopia por resonancia magnética para estudos de neuroquímica psiquiátrica: ventajas e limitaciones. September 8, *16º Congreso Internacional de Psiquiatria*, Buenos Aires, Argentina
40. **Mason GF** (2009) Efectos agudos glutamatérgicos e GABAérgicos de nicotina e álcool en seres humanos. September 9, *16º Congreso Internacional de Psiquiatria*, Buenos Aires, Argentina
41. **Mason GF** (2009) Acute effects of nicotine and ethanol on brain metabolism. October 16, University of Cincinnati, Ohio
42. **Mason GF** (2010) Effects of ethanol on brain metabolism. January 18, *International Conference on Alcoholism*, Yale University, New Haven, Connecticut.
43. **Mason GF** (2010) MRS studies of metabolism in awake animals. March 15, *Symposium on Quantitative Neuroscience with Magnetic Resonance (QNMR)*. Yale University, New Haven, Connecticut
44. **Mason GF** (2010) Acute effects of nicotine and alcohol on amino acid neurotransmitters. March 17, *Behavioral Health Grand Rounds*, Waterbury Hospital, Waterbury, Connecticut
45. **Mason GF** (2010) Acetate transport and utilization in the Brain: characterization and ability to change. September 15, *International Society of Biomedical Research on Alcoholism (ISBRA)*, Paris, France
46. **Mason GF** (2011) Efeitos neuroquímicos do álcool e da nicotina observados *in vivo* com ressonância magnética. April 26, *Instituto de Ciências Humanas, Universidade Federal de Juiz de Fora*, Juiz de Fora, Brazil
47. **Mason GF** (2011) Compartmental analysis and sensitivities of kinetic carbon-13 labeling studies. August 29, *International Society of Neurochemistry*, Athens, Greece
48. **Mason GF** (2011) Espectroscopia por ressonância magnética: teoria e aplicação ao estudo dos efeitos cerebrais de étanol em dose aguda. November 4, *Congresso Brasileiro de Psiquiatria*, Rio de Janeiro, Brazil
49. **Mason GF** (2011) Efeitos agudos de étanol no cérebro investigados pela técnica de espectroscopia de ressonância nuclear, November 3, Universidade Federal de Rio Grande do Sul, Porto Alegre, Brazil
50. **Mason GF** (2011) Efeitos agudos de étanol no cérebro investigados pela técnica de espectroscopia de ressonância nuclear, November 3, Universidade Metodista de Porto Alegre, Porto Alegre, Brazil
51. **Mason GF** (2012) Alcohol, nicotine, and amino acid neurotransmitters, April 24th, *American Society of Neuroradiology*, New York
52. **Mason GF** (2013) Acute and Chronic Energetic Effects of Alcohol on the Brain, February 16, 3rd *International Conference on Applications of Neuroimaging to Alcoholism*, Yale University, New Haven, Connecticut
53. **Mason GF** (2013) Ethanol, its Metabolism, and the Brain, March 5th, *Neuroscience Seminar*, McLean Hospital, Harvard University, Boston, Massachusetts
54. **Mason GF** (2013) Alcohol and the Brain: a Metabolic Perspective, June 23rd, in Symposium “Alcohol and Calories in Alcohol Use and Related Disorders” *Research Society on Alcoholism*, Orlando, Florida
55. **Mason GF** (2013) Metabolic Kinetics in Psychiatric Disease, September 10th, in workshop *Dynamic Imaging and Spectroscopy of Psychiatric Illness*, by Psychiatric MR Study Group in the *International Society of Magnetic Resonance in Medicine*, Lisbon, Portugal
56. **Mason GF** (2013) MR Spectroscopy and Imaging for Beginners – part 1/2, September 9th, in workshop *Dynamic Imaging and Spectroscopy of Psychiatric Illness*, by Psychiatric MR Study Group in the *International Society of Magnetic Resonance in Medicine*, Lisbon, Portugal
57. **Mason GF** (2013) MR Spectroscopy and Imaging for Beginners – part 2/2, September 10th, in workshop *Dynamic Imaging and Spectroscopy of Psychiatric Illness*, by Psychiatric MR Study Group in the *International Society of Magnetic Resonance in Medicine*, Lisbon, Portugal
58. **Mason GF** (2014) Measurement of Heterogeneous Metabolism by ¹³C Magnetic Resonance Spectroscopy: Practicalities and Strategies. July 27, in *Stable Isotope Resolved Metabolomics Symposium*, University of Kentucky, Lexington, KY
59. **Mason GF** (2014) Alcohol and Brain Metabolism. November 6th. *Addiction Neuroscience Seminar*, Medical University of South Carolina, Charleston, SC

60. **Mason GF** (2015) Brain Oxidation of Ethanol and Acetate: Influence of Chronic Alcohol Exposure. April 14. Indiana University – Purdue University Indianapolis.
61. **Mason GF** (2015) ^{13}C MRS Studies of Brain Metabolism of Alcohol and Acetate. May 1. *Visual Brain Core Seminar Series*, University of Alabama at Birmingham, Birmingham, AL
62. **Mason GF** (2015) Magnetic Resonance Spectroscopy of Brain Metabolism of Glucose, Acetate, and Ethanol. December 3. *Distinguished Lecture for Neuroscience and Imaging*, University of Georgia at Athens, Athens, GA
63. **Mason GF** (2016) Principles of Metabolic Modeling of Isotopic Labeling. February 27. The Fourth International Workshop on Hyperpolarized Carbon-13 and Its Applications in Metabolic Imaging, University of Pennsylvania, Philadelphia, PA
64. **Mason GF** (2016) Relationships of Glutamate Concentrations with Glutamatergic Firing, in symposium *Modulation of Glutamate in Task Active States in Humans: Applications to Psychiatry with Real-time Functional MRS*. May 12. *Society of Biological Psychiatry*, Atlanta, GA
65. **Mason GF** (2016) Practical Aspects of ^{13}C MR Studies, August 14, in workshop *MR Spectroscopy: From Current Best Practice to Latest Frontiers*, by *International Society of Magnetic Resonance in Medicine*, Lake Constance, Germany.
66. **Mason GF** (2016) Alcohol-Related Disorders: A Metabolic Perspective. September 13. *Grand Rounds, Lincoln Hospital*, New York, NY.
67. **Mason GF** (2017) Basic NMR Theory. February 28. *Elucidata, Inc.*, Delhi, India.
68. **Mason GF** (2017) ^{13}C Studies of Metabolism In Vivo: Nuclear Magnetic Resonance (NMR) Spectroscopy and Mathematical Modeling. February 28. *Elucidata, Inc.*, Delhi, India.
69. **Mason GF** (2017) Grantcraft: The art of writing a successful grant proposal. *Berlin Institute of Health*, March 31, Berlin, Germany
70. **Mason GF** (2017) The first steps to getting your own money. April 1, *Society for Cerebral Blood Flow & Metabolism*, Berlin, Germany
71. **Mason GF** (2017) Effects of alcohol and nicotine on brain metabolism. April 4, *Neuroscience Seminar*, McLean Hospital, Harvard University, Boston, Massachusetts
72. **Mason GF** (2017) A metabolic perspective of alcohol dependence and withdrawal. April 28, *All India Institute of Medical Science*, Delhi, India
73. **Mason GF** (2017) Alcohol and Brain Metabolism. May 10, *Center for Comparative Neuroimaging*, University of Massachusetts, Worcester, Massachusetts
74. **Mason GF** (Early Life Stress and Glutamate Neurotransmission in Major Depressive Disorder) A Metabolic Perspective of Alcohol Use and Dependence. March 8, *Danish Society for Neuroscience*, University of Copenhagen, Denmark
75. **Mason GF** (2018) Potential for Ketone Bodies to Support Sobriety from Alcohol. March 9, *Psychiatric Centre Copenhagen*, Rigshospitalet, University of Copenhagen, Denmark
76. **Mason GF** (2018) Efeitos Neuroquímicos do Álcool Observados in vivo com Ressonância Magnética. August 31, *Programa de Pós-graduação em Saúde*, Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
77. **Mason GF** (2018) Metabolic Modeling of ^{13}C Hyperpolarized Data for Studying Brain Metabolism and Neurotransmission. October 19, *The Fifth International Workshop on Metabolic Imaging*, University of Pennsylvania, Philadelphia, PA
78. **Mason GF** (2018) ^{13}C Labeling Studies and Challenges of Spectral and Kinetic Fitting. November 30, Second Annual INSPECTOR Workshop, Columbia University, New York, New York
79. **Mason GF** (2019) Alcohol metabolism and the brain: implications for addiction and withdrawal. March 22, *Biosciences Division seminar*, Stanford Research Institute, Menlo Park, California
80. **Mason GF** (2019) Alcohol provides brain energy via oxidation of ethanol and hepatically derived acetate. Ketones can also meet those needs, in symposium *Alcohol Metabolism and the role of Ketone Bodies to Alleviate Symptoms of Alcohol Withdrawal*, Research Society on Alcoholism, June 24, Research Society on Alcoholism, Minneapolis, Minnesota
81. **Mason GF** (2019) Practicalities of getting your first funding. *OSP Funding and Grantsmanship Training Series*, November 8, Yale University
82. **Mason GF**, Sinha R (2021) Establishing a thriving research laboratory. *Yale Center for Clinical Investigation Training Program*, July 19, Yale University

83. **Mason GF** (2021) Of Rats and People: Strategies for Compartmental Metabolic Analysis in the Brain. *Advanced Imaging Research Center Seminar Series*, November 16, University of Dallas, Texas.
84. **Mason GF**, Constable T (2022) Getting your first R01. *Janeway Society First Fridays, Office of Physician-Scientist and Scientist Development*, February 4, Yale University
85. **Mason GF** (2022) Alcohol and Brain Metabolism. *UCLA Brain Research Institute MRS Seminar*, March 2, University of California Los Angeles
86. **Mason GF** (2022) Álcool e Metabolismo Cerebral. *Série de Pós-Graduação em Neurociências*, March 24, Universidade Federal de Rio Grande do Sul, Brazil
87. **Mason GF**, James C.K. Lai (2022) Non-Linear Estimation of Enzyme Kinetics. *James C.K. Lai Retirement Memorial Symposium*, Biomedical and Pharmaceutical Sciences Department, College of Pharmacy, Idaho State University, May 11.
88. **Mason GF** (2022) Cerebral oxidation of ethanol is similar in rats and humans and rises with heavy alcohol consumption. *Research Society on Alcoholism*, Orlando, Florida, June 27
89. **Mason GF** (2022) Brain Alcohol Consumption and its Implications to Support Sobriety. *Division of Neuroscience Seminar Series*, Oregon Health Sciences University, November 29
90. **Mason GF** (2023) Alcohol and Cerebral Metabolism: Potential for Abuse/Support for Detoxification. *Alcohol Training Grant Symposium*, University of Texas at Austin, Austin, TX, February 27.
91. **Mason GF** (2024) Alcohol: Toxic Fuel for the Brain, plus a New Way to Think about Withdrawal. *Gwynn Lecture*, University of Texas Health Science Center, February 21.
92. **Mason GF** (2024) Alcohol as a Brain Fuel: Energy and Toxicity. University of North Carolina at Chapel Hill, May 22.

ABSTRACTS SUBMITTED AND PRESENTED ORALLY

1. **Mason GF**, Behar KL, Boehm DA, Shulman RG (1990) *In vivo* measurement of intracerebral glucose by ^{13}C and ^1H NMR. *Proc Soc Magn Reson Med 9th Annual Mtg*, p. 69
2. **Mason GF**, Rothman DL, Behar KL, Shulman RG (1990) Study of brain metabolism with ^{13}C labeling data and a mathematical model. *Proc Soc Magn Reson Med 9th Annual Mtg*, p. 211
3. **Mason GF**, Behar KL, Martin MA, Shulman RG (1992) ^{13}C NMR measurement of glucose transport kinetics in rat brain during pentobarbital anesthesia. *Proc Soc Magn Reson Med 11th Annual Mtg*, p. 549
4. **Mason GF**, Pan JW, Hetherington HP, Ponder S, Twieg D, Pohost G (1993) Shot-echo spectroscopic imaging of glutamate at 4.1T in human brain in vivo. *Proc Soc Magn Reson Med 12th Annual Mtg*, p. 368
5. **Mason GF**, Gruetter R, Novotny EJ, Rothman DL, Behar KL, Shulman RG (1993) NMR determination of the TCA cycle rate in human brain in vivo by ^{13}C NMR. *Proc Soc Magn Reson Med 12th Annual Mtg*, p. 322
6. **Mason GF**, Harshbarger T, Hetherington HP, Pohost G, Twieg D (1994) Spiral snapshot imaging with unshielded gradients. *Proc Soc Magn Reson 2nd Annual Mtg*, p. 31
7. **Mason GF**, Pan JW, Chu WJ, Khazaeli MB, Williams R, Newcomer BD, Orr R, Conger K, Pohost GM, Hetherington HP (1996) TCA cycle rate measurement in human brain by indirect ^{13}C detection with a volume coil. *Proc Intern Soc Magn Reson Med 4th Annual Mtg*, p. 407
8. **Mason GF**, Pan JW, Chu WJ, Zhang YT, Newcomer BD, Hetherington HP (1997) Tissue-type dependence of human TCA cycle activity in grey matter and white matter measured *in vivo* at 4.1T with a volume coil. *Proc Intern Soc Magn Reson Med 5th Mtg*, p. 402
9. **Mason GF**, Pan JW, Chu W-J, Newcomer BR, Zhang Y, Hetherington HP (1999) Glutamate turnover, oxidation in human grey and white matter by $^1\text{H}/^{13}\text{C}$ MRS. *Biol Psychiatry Annual Mtg*
10. **Mason GF** (1999) T_1 -Based Segmentation of Brain Tissue with a Surface Coil. *Proc Intern Soc Magn Reson Med*, p. 123
11. **Mason GF**, Petersen K, Shen J, Behar KL, Petroff OAC, Shulman GI, Rothman DL (2000) Measurement of the Rate of Pyruvate Carboxylase In Human Brain by ^{13}C MRS. *Biological Psychiatry* 47: 92S
12. **Mason GF**, K Petersen, J Shen, KL Behar, OAC Petroff, GI Shulman, DL Rothman (2000) Measurement of the Rate of Pyruvate Carboxylase in Human Brain by ^{13}C NMR. *Intern Soc Magn Reson Med*, p. 422
13. **Mason GF**, Sanacora G, Anand A, Epperson N, Goddard A, Rothman DL, Charney D, Krystal J (2000) Cortical GABA Differs Between Unipolar And Bipolar Depression. *Intern Soc Magn Reson Med*, p. 521
14. **Mason GF**, Anand A, Sanacora G, Epperson N, Haga K, Appel M, Goddard AW, Charney DS, Rothman DL, Krystal JH (2001) Different relationships among cortical amino acids in unipolar and bipolar depression. *Proc Intern Soc Magn Reson Med* p. 557

15. **Mason GF**, Sanacora G, Hundal R, Appel M, Rothman DL, Krystal JH (2001) Measurement of cortical GABA and glutamate turnover alterations in vivo in major depression using ^{13}C -MRS. Hot Topics session of *American College Neuropsychopharmacology*, Kona, Hawaii, p. 202
16. Goddard AW, **Mason G**, Appel M, Rothman DL, Gueorguieva R, Behar KL, Krystal JH (2001) Reduced cortical GABA neuronal response to benzodiazepine administration in panic disorder. *Annual Meeting of the American College of Neuropsychopharmacology*, Kona, Hawaii, p. 202
17. **Mason GF**, Sibson NR, Behar KL, Hyder F, Sze A, Shulman RG, Rothman DL (2003) Nicotine increases glutamate-glutamine neurotransmitter cycling in rat brain in vivo. *Soc of Biological Psychiatry*, abstract 323
18. **Mason GF**, Appel M, de Graaf RA, Ruff E, Rothman DL, Krystal JH (2003) Brain GABA falls with sobriety in alcohol-dependent subjects. *Proc Intern Soc Magn Reson Med*, p. 147
19. **Mason GF**, Epperson CN, Anand A, Blumberg H, Appel M, Rothman DL, Krystal JH, Sanacora G (2003) Brain GABA differs by subtype of depression. *Proc Intern Soc Magn Reson Med*, p. 142
20. **Mason GF**, Appel M, de Graaf RA, Petrakis I, Ruff E, Rothman DL, Krystal JH (2003) Brain GABA Falls by 1 Month of Detoxification and Remains Low. *Alcohol Clin Exp Res* 27 (Suppl): 56A
21. **Mason GF**, Petersen K, de Graaf RA, Shulman GI, Rothman DL (2003) Anaplerosis in the Human Brain. *Workshop on Dynamic Spectroscopy and Measurements of Physiology, Metabolism, and Function*, p. 18, Orlando, Florida, p. 18
22. **Mason GF**, Petersen KF, Rothman DL, Shulman GI (2004) Increased monocarboxylic acid transport and utilization by the brain in Type 1 diabetics during hypoglycemia: a possible mechanism for hypoglycemia unawareness. *American Diabetes Association*, Orlando, FL, abstract #180-OR, presented June 6, 2004
23. **Mason GF** (2005) MR Spectroscopic Studies of GABA and Glutamate in Psychiatry, August 22, Innsbruck, Austria, *International Society for Neurochemistry*, abstract #W3.C, p. 24 of the proceedings
24. **Mason GF**, Boumezbear F, Sanacora G, Guidone E, Watzl J, Novotny E, Weinzimer S, Shulman I, Krystal JH, Rothman DL, O'Malley S (2007) Acute nicotine stimulates GABA synthesis in human brain. *Proc Intern Soc Magn Reson Med*, p. 770
25. **Mason GF**, Watzl J, Weinzimer S, Sanacora G, Guidone E, Petrakis IL, Rothman DL, Krystal JH (2009) Acute Ethanol Alters GABA and Myoinositol in Human Brain. *Proc Intern Soc Magn Reson Med*, p. 433
26. Gomez R, Watzl J, Behar KL, Weinzimer S, Sanacora G, Guidone E, Petrakis IL, Krystal JH, **Mason GF** (2009) Acute neurochemical effects of ethanol in humans. *American College of Neuropsychopharmacology Hot Topics*, December 6, Hollywood, Florida

ABSTRACTS

1. **Mason GF**, Behar KL, Boehm DA, Shulman RG (1990) In vivo measurement of intracerebral glucose by ^{13}C and ^1H NMR. *Proc Soc Magn Reson Med 9th Annual Mtg*, p. 69
2. Rothman DL, Novotny EJ, Shulman GI, Howseman AM, **Mason GF**, Petroff OAC, Hanstock CC, Prichard JW, Shulman RG (1990) Determination of human brain glutamate turnover times with ^1H NMR. *Proc Soc Magn Reson Med 9th Annual Mtg*, p. 986
3. Shulman RG, Behar KL, Rothman DL, **Mason GF** (1991) NMR studies of cerebral metabolism. NIAAA Workshop on Imaging in Alcohol Research, Wild Dunes, South Caroline, May 9-11
4. **Mason GF**, Behar KL, Martin MA, Shulman RG (1992) ^{13}C NMR measurement of glucose transport kinetics in rat brain during pentobarbital anesthesia. *Proc Cerebral Vascular Biology Conference: Frontiers in Cerebral Vascular Biology - Transport and its Regulation*. Organized by Lester Drewes and Lorris Betz. July 11-13, 1992, Duluth, Minnesota. p. 15
5. Gruetter R, Novotny EJ, Boulware SD, Rothman DL, **Mason GF**, Shulman GI, Tamborlane WM, Shulman RG (1992) Noninvasive measurements of the cerebral steady-state glucose concentration and transport in humans by ^{13}C nuclear magnetic resonance. *Proc Cerebral Vascular Biology Conference: Frontiers in Cerebral Vascular Biology - Transport and its Regulation*. Organized by Lester Drewes and Lorris Betz. July 11-13, 1992, Duluth, Minnesota. p. 14
6. **Mason GF**, Behar KL, Martin MA, Shulman RG (1993) Ketone bodies reduce glutamate steady state enrichments in rat brain following metabolism of $[1-^{13}\text{C}]$ glucose. *Proc Soc Magn Reson Med 12th Annual Mtg*, p. 1513
7. Hetherington HP, Pan JW, **Mason GF**, Ponder SL, Twieg DB, Vaughan JT, Pohost GM (1993) A sequence for high resolution ^1H spectroscopic imaging without FOV restriction: imaging the human brain with 0.5 cc voxels at 4.1T. *Proc Soc Magn Reson Med, 12th Annual Mtg*, p. 901

8. Hetherington HP, Pan JW, **Mason GF**, Ponder SL, Twieg DB, Vaughan JT, Pohost GM (1993) High resolution ^1H spectroscopic imaging of human brain at high field: quantitative evaluation of gray and white matter metabolite differences. *Proc Soc Magn Reson Med, 12th Annual Mtg*, p. 127
9. Pan JW, Hetherington HP, **Mason GF**, Whitaker JN, Pohost GM (1993) Evaluation of multiple sclerosis by high field spectroscopic imaging. *Proc Soc Magn Reson Med, 12th Annual Mtg*, p. 127
10. **Mason GF**, Pohost G, Hetherington H (1994) Cerebral grey/white matter T_2 in SI with 0.5 cc voxels: high resolution, numerically optimized measurements. *Proc Soc Magn Reson, 2nd Mtg*, p. 1172
11. Chen W, Novotny EJ, Boulware SD, Rothman DL, **Mason GF**, Zhu X-H, Blamire AM, Prichard JW, Shulman RG (1994) Quantitative measurements of regional TCA cycle flux in visual cortex of human brain using ^1H - $\{^{13}\text{C}\}$ NMR spectroscopy. *Proc Soc Magn Reson, 2nd Mtg*, p. 63
12. Hetherington HP, Kuzniecky R, Pan JW, **Mason GF**, Vaughan JT, Pohost GM (1994) Identification of the epileptic focus in temporal lobe epilepsy by high resolution spectroscopic imaging at 4.1T. *Proc Soc Magn Reson, 2nd Mtg*, p. 396
13. Novotny EJ, Ariyan C, Rothman DL, Haddad GG, **Mason GF**, Lai JC, Behar KL (1995) NMR spectroscopic studies of the ontogeny of cerebral glucose metabolism in the rat. *Soc Magn Reson Workshop on Advances in Physiol Chem by In Vivo NMR*, March 22-23
14. Martin MA, **Mason GF**, Behar KL, Shulman RG (1995) Measurement of glutamate-glutamine substrate cycle in rat brain by in vivo ^{13}C NMR. *Soc Magn Reson Workshop on Advances in Physiol Chem by In Vivo NMR*, March 22-23
15. Pan JW, **Mason GF**, Pohost GM, Hetherington HP (1995) J-Refocused spectroscopic imaging of human cerebral glutamate at 4.1T. *Eighth Annual Symposium on in vivo MR Spectroscopy, Cape Cod, MA*, March 20-22
16. **Mason GF**, Deutsch G, Mountz J, Harrell L, Pan J, Pohost G, Hetherington H (1995) Severed, disperse neuronal loss in mild AD. *Proc Soc Magn Reson, 3rd Mtg*, p. 1812
17. **Mason GF**, Chu WJ, Hugg JW, Pohost GM, Hetherington HP (1995) Multi-slice image segmentation of human brain. *Proc Soc Magn Reson, 3rd Mtg*, p. 1972
18. Hetherington HP, **Mason GF**, Pan JW, Twieg DB, Adams D, Pohost GM (1995) Quantitative high resolution spectroscopic imaging of human brain at 4.1T. *Proc Soc Magn Reson, 3rd Mtg*, p. 254
19. Pan JW, **Mason GF**, Pohost GM, Hetherington HP (1995) Measurements of human cerebral glutamate by J-refocused spectroscopic imaging at 4.1T. *Proc Soc Magn Reson, 3rd Mtg*, p. 330
20. Hugg JW, Kuzniecky RI, **Mason GF**, Pan JW, Hetherington HP (1995) Temporal lobe epilepsy studied by ^1H MRSI at 4.1T: localization before and follow-up after surgery. *Proc Soc Magn Reson, 3rd Mtg*, p. 1830
21. Hugg JW, Kuzniecky RI, **Mason GF**, Hetherington HP (1995) Mapping of T_1 , T_2 , and T_2^* at 4.1T: application to temporal lobe epilepsy. *Proc Soc Magn Reson, 3rd Mtg*, p. 1067
22. Novotny EJ, Ariyan C, Rothman DL, Haddad GG, **Mason GF**, Lai JC, Behar KL (1995) NMR spectroscopic studies of the ontogeny of cerebral glucose metabolism in the rat. *Proc Soc Magn Reson, 3rd Mtg*, p. 1784
23. Martin MM, **Mason GF**, Behar KL, Shulman RG (1995) Measurement of glutamate-glutamine substrate cycle in rat brain by in vivo ^{13}C NMR. *Proc Soc Magn Reson, 3rd Mtg*, p. 1783
24. Hyder F, Chase JR, Behar KL, **Mason GF**, Rothman DL, Shulman RG (1995) Increased tri-carboxylic acid cycle flux in rat brain during fore-paw stimulation: an *in vivo* ^1H - ^{13}C NMR spectroscopic study. *Proc Soc Magn Reson, 3rd Mtg*, p. 269
25. Hyder F, Chase JR, Behar KL, **Mason GF**, Rothman DL, Shulman RG (1995) Increased tri-carboxylic acid cycle flux in rat brain during fore-paw stimulation: an *in vivo* ^1H - ^{13}C nuclear magnetic resonance spectroscopy study. *Proc Soc Cereb Blood Flow Metab (supplement)* 15: S76
26. Mountz JM, Deutsch G, Inampudi C, San Pedro E, **Mason GF**, Hetherington H, Mennemeier M, Richards JS (1995) Evaluation of the metabolic components of the stroke penumbra by Tc-99m HMPAO SPECT and 4.1T ^1H spectroscopy. *Assn. Of University Radiologists, 44th Mtg*
27. Hugg JW, Kuzniecky RI, Hetherington HP, **Mason GF**, Pan JW, Morawetz RB, Gilliam GF, Faught E (1995) Temporal lobe epilepsy localization by ^1H MRSI at 4.1T with follow-up after surgery. *Proc Am Epil Soc* (presented Dec. 4)
28. Manor D, Behar K, Rothman D, **Mason G**, Hooten M, Krystal J (1995) Ketamine effects on cortical tricarboxylic acid (TCA) cycle rates and GABA metabolism in rats assessed using magnetic resonance spectroscopy. *American College of Neuropsychopharmacology Abstracts of Posters and Panels 34th Annual Meeting*. San Juan, PR, December 11-15. p. 183

29. Manor D, Rothman DL, **Mason GF**, Hyder F, Petroff OAC, Behar KL (1995) GABA synthesis in the rat cortex is reduced 24 hours following inhibition of GABA transaminase. *J Neurochem* 66 (suppl. 1): S81
30. Martin MA, **Mason GF**, Behar KL, Shulman RG (1996) Glutamate-glutamine substrate cycling in rat brain by in vivo ^{13}C NMR spectroscopy. *American Association for the Advancement of Science 1996 Mtg*, p. A-124
31. Manor D, Behar KL, Rothman DL, **Mason GF**, Hooten M, Krystal J (1996) Evaluation of ketamine effects on cortical tricarboxylic acid cycle rate and GABA metabolism in rats using MR spectroscopy. *Proc Soc Magn Reson*
32. **Mason GF**, Pan JW, Chu W-J, Zhang YT, Khazaeli MB, Williams R, Newcomer BD, Orr R, Conger K, Pohost GM, Hetherington HP (1996) TCA cycle rate measurement in human brain by indirect ^{13}C detection with a volume coil. *Internat Soc Magn Reson Med, 4th Mtg*, p. 407
33. **Mason GF**, Chu W-J, Pohost GM, Hetherington HP (1996) A general approach to numerically optimized experiment design, used for multi-slice imaging of T_1 in human brain at 4.1T. *Internat Soc Magn Reson Med, 4th Mtg*, p. 1555
34. Pan JW, **Mason GF**, Vaughan JT, Pohost GM, Hetherington HP (1996) ^{13}C editing of glutamate in human brain using J-refocused coherence transfer spectroscopy at 4.1T. *Internat Soc Magn Reson Med, 4th Mtg*, p. 379
35. Chu W-J, Hetherington HP, Vaughan JT, Kuzniecky RI, **Mason GF**, Twieg DB, Elgavish GA (1996) High resolution in vivo ^{31}P spectroscopy of temporal lobe epilepsy on 4.1 Tesla whole body NMR. *Internat Soc Magn Reson Med, 4th Mtg*, p. 133
36. Sibson NR, Dhankar A, **Mason GF**, Behar KL, Rothman DL, Shulman RG (1996) An in vivo ^{13}C NMR spectroscopy study of cerebral metabolism in the hyperammonaemic rat. *Internat Soc Magn Reson Med, 4th Mtg*, p. 99
37. Moore G, Zhang Y, Kidambi S, **Mason GF**, Harshbarger T, Pohost GM, Twieg D (1996) constrained detection of activation along the cerebral cortical shell by fMRI. *Internat Soc Magn Reson Med, 4th Mtg*, p. 1621
38. McIntosh J, Zhang Y, Kidambi S, Harshbarger T, **Mason GF**, Pohost GM, Twieg D (1996) Echo-time dependence of the functional MRI "fast response". *Internat Soc Magn Reson Med, 4th Mtg*, p. 284
39. Kidambi S, Gamlin P, Zhang Y, Hetherington HP, **Mason GF**, Pohost GM, Twieg D (1996) fMRI detection of frontal eye field activation during saccadic eye movements. *Internat Soc Magn Reson Med, 4th Mtg*, p. 1844
40. Manor D, Rothman DL, **Mason GF**, Hyder F, Petroff OAC, Behar KL (1996) The rate of turnover of cortical GABA from $[1-^{13}\text{C}]$ glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (γ -vinyl GABA). *Internat Soc Magn Reson Med, 4th Mtg*, p. 98
41. Manor D, Behar KL, Rothman DL, **Mason GF**, Hooten M, Krystal J (1996) Evaluation of ketamine effects on cortical tricarboxylic acid cycle rate and GABA metabolism in rats using MR spectroscopy. *Internat Soc Magn Reson Med, 4th Mtg*, p. 904
42. **Mason GF**, Pan JW, Chu WJ, Zhang YT, Newcomer BD, Hetherington HP (1997) Tissue-type dependence of human TCA cycle activity in grey matter and white matter measured in vivo at 4.1T with a volume coil. *Internat Soc Magn Reson Med, 5th Mtg*, p. 402
43. Chu W-J, **Mason GF**, Hetherington HP (1997) Phosphorus metabolite differences in gray and white matter: ^{31}P NMR spectroscopic imaging studies of human brain at 4T. *Internat Soc Magn Reson Med, 5th Mtg*, p. 1407
44. Mountz JM, **Mason GF**, San Pedro EC, Deutsch G, Inampudi C, Hetherington HP (1997) Characterization of rest and diamox rCBF SPECT findings on cerebral infarction complemented by ^1H spectroscopic imaging. *Internat Soc Magn Reson Med, 5th Mtg*, p. 1177
45. Sibson NR, Dhankar A, Shen J, **Mason GF**, Behar KL, Rothman DL, Shulman RG (1997) In vivo evidence for a cerebral glutamate-glutamine cycle. ^{13}C NMR measurement of glutamine synthesis during high-dose pentobarbital anesthesia. *Internat Soc Magn Reson Med, 5th Mtg*, p. 1266
46. **Mason GF** (1997) Effects of pyruvate carboxylase on ^{13}C NMR measurements of the TCA cycle rate. *Brain Energy Metabolism Satellite Meeting of American/International Soc Neurochem*, p. 14
47. Hyder F, Rothman DL, **Mason GF**, Boucher RB, Behar KL, Shulman RG (1997) Glucose oxidation in rat brain: a functional MRS and MRI study. *Brain Energy Metabolism Satellite Meeting of American/International Soc Neurochem*, p. 7

48. Sibson NR, Dhankhar A, Rothman DL, **Mason GF**, Behar KL, Shulman RG (1997) Stoichiometry of cerebral energy metabolism and neurotransmitter cycling *in vivo*. *Brain Energy Metabolism Satellite Meeting of American/International Soc Neurochem*, p. 20
49. Chu W-J, **Mason GF**, Pan JW, Hetherington HP, San Pedro EC, Mountz JM (1998) ¹H spectroscopic imaging of gray and white matter of normal aging brain at 4.1T. *Proc Internat Soc Magn Reson Med*, 6th Mtg, p. 543
50. Sibson NR, Dhankhar A, **Mason GF**, Behar KL, Rothman DL, Shulman RG (1998) Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity determined by *in vivo* ¹³C NMR spectroscopy. *Proc Internat Soc Magn Reson Med*, 6th Mtg, p. 327
51. Shen J, Sibson NR, **Mason GF**, Shulman RG, Behar KL, Rothman DL (1998) Two-compartment modeling of glutamate-glutamine cycle using *in vivo* ¹³C NMR spectroscopy. *Proc Internat Soc Magn Reson Med*, 6th Mtg, p. 1761
52. Shen J, Peterson KF, Behar KL, Brown PB, Nixon TW, **Mason GF**, Petroff OAC, Shulman GI, Shulman RG, Rothman DL (1998) Measurement of ¹³C glutamate and glutamine turnover in human brain at 2.1T with enhanced sensitivity. *Proc Internat Soc Magn Reson Med*, 6th Mtg, p. 541
53. Hyder F, Kennan RP, Sibson NR, **Mason GF**, Behar KL, Rothman DL, Shulman RG (1998) Cerebral oxygen delivery *in vivo*: NMR measurements of CBF and CMR_{O2} at different levels of brain activity. *Proc Internat Soc Magn Reson Med*, 6th Mtg, p. 1160
54. **Mason GF** (1998) [¹³C]-MR spectroscopy of glutamate, glutamine, and GABA turnover: implications for psychiatry. *Biol Psychiatry* 43 (supplement): 8S
55. Sanacora G, Goddard AW, Gil R, D'Souza DC, Abi-Saab W, Petroff OAC, Mattson R, **Mason GF**, Behar KL, Ciarcia J, Berman R, Charney DS, Rothman D, Krystal JH (1998) Quantification of cortical GABA levels in neuropsychiatric patients. *Biol Psychiatry* 43 (supplement): 8S
56. Krystal JH, Behar K, Abi-Dargham A, Petrakis IL, Laruelle M, Trevisan L, D'Souza DC, **Mason G**, Krasnicki S, Seibyl JP, Baldwin R, Charney DS, Innis R, Rothman D (1998) GABAergic and glutamatergic alterations in alcohol-dependent patients. *American College of Neuropsychopharmacology*, December 14-18, Croabas, Puerto Rico
57. **Mason G**, Sibson N, Hyder F, Shen J, Behar K, Krystal J, Shulman R, Rothman D (1998) The relationship of amino acid neurotransmission, neuronal metabolism, and cerebral blood flow. *American College of Neuropsychopharmacology*, December 14-18, Croabas, Puerto Rico
58. Sanacora G, **Mason GF**, Rothman DL, Berman RM, Charney DS, Ciarcia JJ, Krystal JH (1998) ECT effects on cortical GABA levels as determined by ¹H MRS. *American College of Neuropsychopharmacology* December 14-18, Croabas, Puerto Rico
59. Sanacora G, **Mason GF**, Rothman DL, Behar KL, Berman R, Hyder F, Abi-Saab W, Krystal JH (1998) Decreased cortical GABA levels in major depression as determined by ¹H MRS. *Soc Neurosci Annual Mtg, Los Angeles, CA* (November)
60. **Mason GF**, Pan JW, Chu W-J, Newcomer BR, Zhang Y, Hetherington HP (1999) Glutamate turnover, oxidation in human grey and white matter by ¹H/¹³C MRS. *Biol Psychiatry Annual Mtg* (presented orally 5/14/99)
61. Epperson CN, **G Mason**, DR Rothman, G Sanacora, JH Krystal (1999) GABA dysregulation in premenstrual dysphoric disorder? *Annual Meeting of the Society of Biological Psychiatry*, Washington, D.C., 5/14/99
62. Goddard AW, **Mason GF**, Rothman DL, Behar KL, Charney DS, Krystal JH (1999) Cortical GABA levels in panic disorder. *Biol Psychiatry Annual Mtg*
63. **Mason GF**, Pan JW, Chu W-J, Newcomer BR, Zhang Y, Hetherington HP (1999) TCA Cycle Rate Measurement in Human Brain by ¹H{¹³C} NMR in Presence of Partial Volume Effects. *Proc Intern Soc Magn Reson Med*, p. 1422
64. **Mason GF** (1999) T₁-Based Segmentation of Brain Tissue with a Surface Coil. *Proc Intern Soc Magn Reson Med*, p. 123
65. Pan JW, **Mason GF**, Shen J, Telang F, Lee JH, Brown P, Shulman GI, Rothman DL, Hetherington HP (1999) Spectroscopic imaging of glutamate C4 turnover in human brain in photic stimulation. *Proc Intern Soc Magn Reson Med*, p. 296
66. Sibson NR, **Mason GF**, Rothman DL, Behar KL, Shulman RG (1999) ¹³C NMR spectroscopy investigation of the relationship between brain glucose metabolism and glutamatergic neuronal activity under pharmacologically stimulated conditions. *Proc Intern Soc Magn Reson Med*, p. 618
67. Sanacora G, **Mason GF**, Rothman DL, Berman RM, Charney DS, Ciarcia JJ, Krystal JH (1999) ECT effects on cortical GABA levels as determined by 1H-MRS. *Proc Intern Soc Magn Reson Med*, p. 1401

68. Sanacora G, **Mason GF**, Rothman DL, Behar KL, Hyder F, Petroff OAC, Berman RM, Charney DS, Krystal JH (1999) ^1H -Magnetic Resonance Spectroscopy Evidence of Reduced Cortical GABA Levels in Depressed Patients. *Proc Intern Soc Magn Reson Med*, p. 461
69. Hyder F, Kennan RP, Kida I, Sibson NR, **Mason GF**, Behar KL, Shulman RG, Rothman DL (1999) Relationship between cerebral blood flow and oxygen delivery in rat brain: a 7T NMR study. *Proc Intern Soc Magn Reson Med*, p. 294
70. Goddard AW, **Mason GF**, Rothman DL, Behar KL, Charney DS, Krystal JH (1999) Reductions in cortical GABA levels in panic disorder. *Proc Intern Soc Magn Reson Med*, p. 1417
71. Sanacora G, **Mason G**, Petroff OAC, Rothman D, Behar K, Berman R, Charney DS, Krystal JH (1999) Low cortical GABA levels in depressed patients measured with $[^1\text{H}]\text{MRS}$ increased by antidepressant treatment. *Biol Psychiatry Annual Mtg*
72. Hyder F, Rothman DL, Behar KL, **Mason GF** (1999) A microscopic model of cerebral oxygenation. *J Cereb Blood Flow Metab* 19 (Suppl. 1): S724
73. **Mason GF**, Pan J, Chu W-J, Newcomer B, Zhang Y, Hetherington H (1999) Partial volume effects in ^{13}C -labeling studies of human brain. *International Society of Neurochemistry Brain Energy 4th Satellite Conference, Biochemical Society 49th Harden Conference*.
74. **Mason GF** (1999) CWave: new software for analyzing ^{13}C -labeling studies in vivo. International Society of Neurochemistry Brain Energy 4th Satellite Conference, Biochemical Society 49th Harden Conference.
75. Novotny EJ, Hyder F, **Mason G**, Rothman DL (1999) Cerebral gaba in childhood generalized epilepsy. *Society for Neuroscience Abstracts* 25: 602
76. Novotny EJ, Hyder F, **Mason GF**, Rothman DL (1999) Cerebral GABA in childhood generalized epilepsy. *Epilepsia* 40 (Suppl. 7): 125
77. **Mason G**, Sanacora G, Anand A, Epperson N, Goddard A, Rothman D, Charney D, Krystal J (1999) Cortical GABA Differs In Unipolar And Bipolar Depression. *American College of Neuropsychopharmacology*, Dec. 12-16, Acapulco, Mexico, p. 22
78. **Mason GF**, G Sanacora, A Anand, N Epperson, A Goddard, D Rothman, D Charney, J Krystal (2000) Cortical GABA Reduced In Unipolar But Not Bipolar Depression. *Biological Psychiatry* 47: 92S
79. **Mason GF**, Petersen K, Shen J, Behar KL, Petroff OAC, Shulman GI, Rothman DL (2000) Measurement of Human Cortical Gaba Synthesis *In Vivo*. *Biological Psychiatry* 47: 92S
80. **Mason GF**, Petersen K, Shen J, Behar KL, Petroff OAC, Shulman GI, Rothman DL (2000) Measurement of the Rate of Pyruvate Carboxylase In Human Brain by ^{13}C MRS. *Biological Psychiatry* 47: 92S
81. **Mason GF** (2000) T_1 -Based Partial Volume Segmentation of Brain Tissue with a Surface Coil. *Intern Soc Magn Reson Med*, p. 1753
82. **Mason GF**, K Petersen, J Shen, KL Behar, OAC Petroff, GI Shulman, DL Rothman (2000) Measurement of the Rate of Pyruvate Carboxylase in Human Brain by ^{13}C NMR. *Intern Soc Magn Reson Med*, p. 422
83. **Mason GF** (2000) CWave: Software for the Design and Analysis of ^{13}C Labeling Studies Performed *In Vivo*. *Intern Soc Magn Reson Med*, p. 1870
84. **Mason GF**, Sanacora G, Anand A, Epperson N, Goddard A, Rothman DL, Charney D, Krystal J (2000) Cortical GABA Differs Between Unipolar And Bipolar Depression. *Intern Soc Magn Reson Med*, p. 521
85. **Mason GF**, Petersen K, Shen J, Behar KL, Petroff OAC, Shulman GI, Rothman DL (2000) Observation of synthesis of human cortical GABA by ^{13}C NMR. *Intern Soc Magn Reson Med*, p. 1935
86. Novotny EJ Jr, Hyder F, **Mason G**, Rothman DL (2000) Cerebral GABA in childhood generalized epilepsy. *Intern Soc Magn Reson Med*, p. 1149
87. Pan JW, Stein DT, Telang F, Lee JH, Heydari S, **Mason G**, Rothman DL, Hetherington HP (2000) Spectroscopic imaging of metabolism in human grey matter and white matter at 4T. *Intern Soc Magn Reson Med*, p. 419
88. de Graaf RA, Petersen KF, **Mason GF**, Behar KL, Shulman GI, Mattson RH, Rothman DL, Petroff OAC (2000) GABA synthesis and cycling in human brain as studied by ^1H and ^{13}C NMR spectroscopy. *Intern Soc Magn Reson Med*, p. 13
89. Hyder F, Kennan RP, Kida I, **Mason GF**, Behar KL, Rothman DL (2000) Interpretation of brain “deactivation” and “activation” for functional MRI. *Intern Soc Magn Reson Med*, p. 971
90. **Mason GF**, Petersen K, Shen J, Behar KL, Petroff OAC, Shulman GI, Rothman DL (2000) Neurotransmitter synthesis in human brain. *J Neurochem* 74: S35C

91. de Graaf RA, Petersen KF, **Mason GF**, Shen J, Behar KL, Shulman GI, Mattson RH, Rothman DL, Petroff OAC (2000) ^{13}C NMR studies of GABA synthesis after acute vigabatrin treatment in human epilepsy patients. *J Neurochem* 74 (Suppl): S35D
92. **Mason GF**, Sanacora G, Anand A, Epperson N, Goddard A, Rothman D, Charney D, Krystal JH (2000) Distinct alterations in cortical amino acid levels in unipolar and bipolar depression assessed with MRS. *Soc Neurosci abstract* 431.5
93. **Mason GF**, Anand A, Sanacora G, Appel M, Haga K, Epperson N, Goddard A, Rothman D, Charney D, Aghajanian G, Krystal J (2000) GABA, glutamate, and glutamine in bipolar and unipolar depression. *American College of Neuropsychopharmacology*, San Juan, Puerto Rico, Dec. 11th-15th; p. 304
94. Sanacora G, **Mason GF**, Rothman DL, Berman RM, Zimolo Z, Krystal JH (2000) Cortical GABA concentrations are increased in depressed patients following treatment with selective serotonin reuptake inhibitors. *American College of Neuropsychopharmacology*, San Juan, Puerto Rico, Dec. 11th-15th; p. 276
95. Novotny EJ, Hyder F, **Mason G**, Rothman DL. Cerebral GABA in Pediatric Epilepsy. Abstracts of Pediatric Academic Society Meeting May 2000. Pediatric Research.
96. Epperson CN, **Mason G**, Sanacora G, Hauger R, Rothman D, Krystal JH (2000) Preliminary evidence of menstrual cycle fluctuations in cortical GABA levels in healthy women and women with PMDD assessed with MRS: relationship to neurosteroids. *Alc Clin Exp Res* 24(5):48A (#247)
97. Sanacora G., Petroff OAC, **Mason G**, Hyder F, Behar KL, Goddard A, Charney DS, R. Mattson, D.L. Rothman, Krystal JH (2000) Deficits in cortical GABA levels in major depressive disorder, panic disorder, and alcoholism assessed with MRS: potential therapeutic implications of topiramate elevation of GABA levels. *Int J Neuropsychopharmacology* 3(suppl 1): S379 (#P.20.03)
98. **Mason GF**, Haga K, Appel M, Rothman DL, Behar KL, Sanacora G, Epperson N, Goddard A, Anand A, Krystal JH (2001) Measuring cortical GABA levels and neurotransmitter turnover with ^1H -MRS and ^{13}C -MRS. *Soc Biol Psych* 49: 148S
99. **Mason GF**, Petrakis IL, Haga K, Frisbee R, Staley J, Appel M, Rothman DL, Krystal JH (2001) Preliminary evidence of a decline in cortical GABA levels during the initial month of sobriety in alcohol dependent patients: a $[^1\text{H}]$ MRS study. *Biol Psych* 49: 95S
100. Epperson N, Haga K, **Mason GF**, Appel M, Krystal JH (2001) Influences of neurosteroids on cortical GABA levels. *Biol Psych* 49: 148S
101. Haga K, Epperson N, Appel M, Krystal JH, **Mason GF** (2001) Interactions of cortical glutamate and GABA in women with PMDD. *Biol Psych* 49: 42S
102. Haga K, Epperson CN, Rothman DL, Krystal JH, **Mason G** (2001) Alterations in the relationships between cortical amino acids in PMDD *Proc Intern Soc Magn Reson Med* p. 966
103. Epperson CN, Haga K, **Mason GF**, Appel M, Sellers E, Sanacora G, Rothman DL, Krystal JH, Mason GF (2001) Effects of Endogenous and Exogenous Modulators of GABA Receptor Function on GABA Levels: The Menstrual Cycle *Proc Intern Soc Magn Reson Med* p. 965
104. Lebon V, Petersen KF, Cline GW, Shen J, **Mason GF**, Dufour S, Behar KL, Shulman GI, Rothman DL (2001) The use of $[2-^{13}\text{C}]$ acetate to determine the pathway for neurotransmitter glutamate repletion in the human brain. *Proc Intern Soc Magn Reson Med* p. 204
105. Lebon V, Petersen KF, Cline GW, Shen J, **Mason GF**, Dufour S, Behar KL, Shulman GI, Rothman DL (2001) Measurement of the astrocytic tea cycle flux in humans using ^{13}C labeled acetate. *Proc Intern Soc Magn Reson Med* p. 1053
106. **Mason GF**, Anand A, Sanacora G, Epperson N, Haga K, Appel M, Goddard AW, Charney DS, Rothman DL, Krystal JH (2001) Different relationships among cortical amino acids in unipolar and bipolar depression. *Proc Intern Soc Magn Reson Med* p. 557
107. Appel M, deGraaf RA, Rothman DL, **Mason GF** (2001) A method for detecting brain GABA in the presence of motion. *Proc Intern Soc Magn Reson Med* p. 1706
108. Patel AB, de Graaf RA, **Mason GF**, Cline GW, Lebon V, Shulman GI, Shulman RG, Rothman DL, Behar KL (2001) GABAergic and glutamatergic neurotransmitter cycling in the rat cortex. *Proc Intern Soc Magn Reson Med* p. 1031
109. Krystal JH, Sanacora G, Goddard A, Novotny E, Anand A, Epperson CN, Charney D, Rothman D, **Mason G** (2001) Reduced cortical GABA levels in depression. *World J Biol Psychiatry* 2:71S (abstract #S047-06)
110. Krystal JH, Belger A, **Mason G**, Pilowsky L (2001) Neuroimaging strategies for evaluating glutamatergic regulation. *World J Biol Psychiatry* 2: 167S (abstract #S095-03)

111. Sanacora G, **Mason GF**, Rothman DL, Krystal JH (2001) Cortical gaba concentrations are decreased in depression and increase with ECT treatment. World Congress of Psychiatry, Berlin (in press)
112. **Mason GF**, Sanacora G, Hundal R, Petersen K, Shulman GI, de Graaf RA, Rothman DL, Krystal JH (2001) Preliminary evidence of reduced cortical GABA synthesis rate in major depression. *Soc Neurosci* abstract 142.6
113. Sanacora G, **Mason GF**, Rothman DL, Epperson N, Goddard A, Zimolo Z, Heninger G, Krystal JH (2001) Cortical GABA differentiates depressive subtypes. *Soc Neurosci* abstract 785.6
114. Patel AB, Rothman DL, de Graaf RA, Wang B, **Mason G**, Shulman RG, Behar KL (2001) GABA and glutamate neurotransmitter cycling in rat cortex in relation to activity. *Soc Neurosci* abstract 124.4
115. Novotny EJ, Bara-Jiminiz W, Hallett M, Pagan F, Boudreau E, Mason GF, Rothman DL (2001) Cerebral GABA in LaFora disease. *Soc Neurosci* abstract 551.1
116. Petroff OAC, de Graaf RA, Petersen KF, **Mason GF**, R.H Mattson, D.L. Rothman (2001) Glutamate, Glutamine, and GABA Synthesis and Cycling in Epileptic and Non-epileptic Human Brain by Proton & Carbon Magnetic Resonance Spectroscopy. *Epilepsia* 42 (suppl 7): 101
117. **Mason GF**, Sanacora G, Hundal R, Appel M, Rothman DL, Krystal JH (2001) Measurement of cortical GABA and glutamate turnover alterations in vivo in major depression using ¹³C-MRS. *Annual Meeting of the American College of Neuropsychopharmacology* (p. 202)
118. Goddard AW, **Mason G**, Appel M, Rothman DL, Gueorguieva R, Behar KL, Krystal JH (2001) Reduced cortical GABA neuronal response to benzodiazepine administration in panic disorder. *Annual Meeting of the American College of Neuropsychopharmacology* (p. 107)
119. **Mason GF**, Magistretti P, Hetherington HP, Ross BD, Krystal JH (2001) Use of ¹³C-labeled tracers in MRS to characterize neuron-glia interactions in glutamatergic and GABAergic neurotransmission: psychiatric applications. *American College of Neuropsychopharmacology* (p. 97)
120. Sanacora G, **Mason GF**, Rothman DL, Krystal JH (2001) Occipital cortex GABA concentrations differentiate depressive subtypes. *American College of Neuropsychopharmacology* (p. 152)
121. Staley JK, **Mason G**, Petrakis I, Zoghbi SS, Verhoeff NP, Seibyl JP, Van Dyck C, Innis RB, Baldwin RM, Krystal JH (2002) Assessment of cortical GABA function in acutely (< 7 days) detoxified alcohol dependent patients. *Society of Nuclear Medicine*, Los Angeles, CA, June 2002.
122. Staley JK, **Mason G**, Gottschalk PC, Petrakis I, Zoghbi S, Verhoeff NP, Seibyl JP, Van Dyck C, Innis RB, Baldwin RM, Krystal JH (2002) GABAergic dysfunction in recovering alcoholics. *Proc German Soc Addiction Res Therapy*, Berlin, Germany, April 2002
123. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, **Mason GF** (2002) Glutamate and GABA systems as targets for novel antidepressant and mood stabilizing treatments. *Mol Psychiatry* 7: S71-S80
124. **Mason GF**, Petersen KF, de Graaf RA, Kanamatsu T, Otsuki T, Rothman DL (2002) Measurements of the Tricarboxylic Acid Cycle and Glutamate-Glutamine Cycling with Oral Administration of [1-¹³C]Glucose Require Greater Signal-to-Noise Ratios than Intravenous Administration. *Proc International Soc Magn Reson Med* p. 965
125. Appel M, Sanacora G, Rothman DL, Petroff OA, Krystal JH, **Mason GF** (2002) An MRS Study of Brain Homocarnosine Levels in Unipolar Depressed Patients. *Proc International Soc Magn Reson Med*, p. 701
126. de Graaf R, Brown P, **Mason G**, Rothman D, Behar K (2002) Localized, High-Sensitivity, High-Resolution 1H-[¹³C]-NMR Spectroscopy of Rat Brain In Vivo at 7 Tesla. *Proc International Soc Magn Reson Med* p. 586
127. de Graaf R, **Mason G**, Rothman D, Behar K (2002) 1H-[¹³C]-NMR Spectroscopy of [1,6-¹³C₂]-Glucose Metabolism in Rat Brain Gray and White Matter. *Proc Interational Soc Magn Reson Med* p. 943
128. Patel A, de Graaf R, **Mason G**, Rothman D, Kanamatsu T, Wang B, Shulman R, Behar K (2002) Glutamate/glutamine cycle and glucose oxidation increase proportionately in rat cortex during bicuculline-induced seizures. *Soc for Neuroscience* abstract # 36.12
129. **Mason GF**, Sibson NR, Behar KL, Hyder F, Sze A, Shulman RG, Rothman DL (2002) Nicotine increases the rate of glutamate-glutamine cycling and glucose oxidation in rat brain in vivo. *American College of Neuropsychopharmacology*, San Juan, Puerto Rico, December 7-13th
130. **Mason GF**, Sibson NR, Behar KL, Hyder F, Sze A, Shulman RG, Rothman DL (2003) Nicotine increases glutamate-glutamine neurotransmitter cycling in rat brain in vivo. *Soc of Biological Psychiatry*, abstract 323

131. Sanacora G, **Mason GF**, Anand A, Epperson CN, Wu Y-T, Krystal JH (2003) Occipital cortex GABA concentrations differentiate depressive subtypes. *Soc of Biological Psychiatry*, abstract 486
132. Patel AB, de Graaf RA, **Mason GF**, Kanamatsu T, Rothman DL, Shulman RG, Behar KL (2003) Physiological coupling between glutamatergic transmission and glucose oxidation over the entire range of brain activity. *Proc Intern Soc Magn Reson Med*, p. 1970
133. Patel AB, de Graaf RA, **Mason GF**, Rothman DL, Wang B, Shulman RG, Behar KL (2003) Absolute quantification of GABA/glutamine and glutamate/glutamine cycle fluxes in rat cerebral cortex: an in vivo ¹³C NMR study. *Proc Intern Soc Magn Reson Med*, p. 1969
134. **Mason GF**, Appel M, de Graaf RA, Ruff E, Rothman DL, Krystal JH (2003) Brain GABA falls with sobriety in alcohol-dependent subjects. *Proc Intern Soc Magn Reson Med*, p. 147
135. **Mason GF**, Epperson CN, Anand A, Blumberg H, Appel M, Rothman DL, Krystal JH, Sanacora G (2003) Brain GABA differs by subtype of depression. *Proc Intern Soc Magn Reson Med*, p. 142
136. de Graaf RA, **Mason GF**, Rothman DL, Behar KL (2003) Regional ¹H-¹³C-NMR spectroscopy of glucose metabolism in rat brain. *Proc Intern Soc Magn Reson Med*, p. 577
137. Novoty EJ, de Graaf RA, **Mason G**, Appel M, Pearl P, Gibson KM, Rothman DL (2003) Brain GABA in SSADH deficiency. *Proc Intern Soc Magn Reson Med*, p. 332
138. **Mason GF**, Appel M, de Graaf RA, Petrakis I, Ruff E, Rothman DL, Krystal JH (2003) Brain GABA Falls by 1 Month of Detoxification and Remains Low. *Alcohol Clin Exp Res* 27 (Suppl): 56A
139. **Mason GF**, Petersen K, de Graaf RA, Shulman GI, Rothman DL (2003) Anaplerosis in the Human Brain. *Workshop on Dynamic Spectroscopy and Measurements of Physiology, Metabolism, and Function*, Orlando, Florida, p. 18
140. Novotny EJ, de Graaf RA, **Mason GF**, Appel M, Pearl P, Wong K, Gibson KM, Rothman DL (2003) Brain GABA in SSADH deficiency. *Epilepsia* 44 (Suppl 9): 248
141. **Mason GF**, Petrakis I, de Graaf R, Appel M, Gueorguieva R, Ruff E, Coric V, Trevisan L, Rothman D, Krystal J (2003) Smoking effects on cortical GABA levels in ethanol withdrawal. *American College of Neuropsychopharmacology*, p. 194
142. Sanacora G, Fenton L, Fasula M, Rothman DL, Krystal JH, **Mason GF** (2003) Occipital cortex GABA concentrations are not increased following cognitive behavioral therapy for depression. *American College of Neuropsychopharmacology* p. 153
143. Epperson CN, Czarkowski K, Gueorguieva R, Krishnan-Sarin S, Jatlow P, Rothman DL, Krystal JH, O'Malley S, **Mason GF** (2003) Impact of nicotine on cortical GABA levels across the menstrual cycle in female smokers. *Scientific Abstracts, American College of Neuropsychopharmacology 42nd Annual Meeting*, San Juan, PR, pg. 136
144. Epperson N, Czarkowski K, Gueorguieva R, Krishnan-Sarin S, Krystal JH, Rothman DL, O'Malley S, **Mason GF** (2004) Impact of nicotine on cortical GABA levels across the menstrual cycle in female smokers. *Society for Research on Nicotine and Tobacco*, Scottsdale, AZ, Feb. 18th.
145. **Mason GF** (2004) Methodology of Magnetic Resonance Spectroscopy. *International Conference on Applications of Neuroimaging to Alcoholism*
146. Patel AB, de Graaf RA, **Mason GF**, Shulman RG, Behar KL (2004) Increased inhibitory neurotransmission observed during intense neuronal activation in rat cortex: an *ex vivo* ¹³C NMR study. *Intern Soc Magn Reson Med*, abstract #26, p. 7
147. Patel AB, Chowdhury GM, de Graaf RA, **Mason GF**, Rothman DL, Shulman RG, Behar KL (2004) Measurement of anaplerosis in rat cortex during intense synaptic activity: an *in vivo* ¹³C NMR study. *Intern Soc Magn Reson Med*, abstract #2367, p. 441
148. Russ DW, Lanza IR, **Mason G**, Rothman D, Kent-Braun JA (2004) Sex-related differences in human skeletal muscle metabolism during maximum-effort exercise. *Exp Biol*
149. Sanacora G, Joost van Watum, P, Tamborlane WV, Rothman DL, Krystal JH, **Mason GF** (2004) Cortical GABA measures in adolescent subjects with Type 1 Diabetes Mellitus. *Soc Biol Psychiatry*, abstract #649
150. **Mason GF**, Petersen KF, Rothman DL, Shulman GI (2004) Increased monocarboxylic acid transport and utilization by the brain in Type 1 diabetics during hypoglycemia: a possible mechanism for hypoglycemia unawareness. *American Diabetes Association*, Orlando, FL, abstract #180-OR, presented June 6, 2004
151. Krystal JH, Sanacora G, Blumberg H, D'Souza DC, Mathalon D, **Mason G**, Cavus I (2004) Why Do Anticonvulsants Play a Role in the Treatment of schizophrenia and mood disorders? A systems neuroscience Perspective. *44th Ann New Clin Drug Eval Unit (NCDEU) Mtg*

152. **Mason GF**, Behar KL, de Graaf RA, Patel AB, Sibson N, Shulman RG, Rothman DL (2004) Measuring cerebral energy and neurotransmitter metabolism in vivo with nuclear magnetic resonance. *Annual Meeting of the Biomedical Engineering Society*, abstract #421
153. **Mason GF**, Sanacora G, de Graaf RA, Rothman DL, Krystal JH (2005) Light Deprivation Lowers Brain GABA. *Soc Biol Psychiatry* 57: 135S (abstract #490)
154. Sanacora G, **Mason GF**, Gelernter J, Krystal JH, Lappalainen J (2005) Association between functional GAD65 promoter polymorphism and cortical GABA levels in depressed individuals. *Biol Psychiatry* 57: 114S (abstract #417)
155. Sanacora G, Rothman D, Krystal J, **Mason GF** (2005) MRS Studies of Cortical Amino Acid Neurotransmitters in Depression. *World Congress of Biological Psych*, Abstract S-038.01
156. **Mason GF**, Watzl J, Gomez R, Guidone E, Sanacora G, George T, Kibbey R, Shulman G, Krystal J, Rothman D, O'Malley S (2006) Acute nicotine increases occipital cortical GABA. *Alcohol Clin Exp Res* 30: 195A, *Suppl*
157. **Mason GF**, Watzl J, Gomez R, Krystal J, Rothman D, Sanacora G (2006) Effects of light deprivation on GABA and glutamate in healthy and depressed individuals. *Amer Coll Neuropsychopharm*.
158. **Mason GF**, Boumezbeur F, Sanacora G, Guidone E, Watzl J, Novotny E, Weinzimer S, Shulman I, Krystal JH, Rothman DL, O'Malley S (2007) Acute nicotine stimulates GABA synthesis in human brain. *Proc Intern Soc Magn Reson Med*, p. 770
159. **Mason GF**, Watzl J, Gomez R, Guidone E, Sanacora G, George T, Jatlow P, Kibbey R, Shulman G, Krystal JH, Rothman DL, O'Malley S (2007) GABA changes acutely in human brain after nicotine administration. *Proc Intern Soc Magn Reson Med*, p. 2251
160. Boumezbeur F, Petersen KF, Shulman GI, Rothman DL, **Mason GF** (2007) Measurement of GABA/glutamine cycling rate in the human brain using ^{13}C MRS. *Proc Intern Soc Magn Reson Med*, p. 361
161. **Mason GF**, Boumezbeur F, Sanacora G, Guidone E, Watzl J, Gomez R, Novotny E, Weinzimer S, Shulman GI, Krystal JH, Rothman DL, O'Malley S (2007) Nicotine increases GABA synthesis in human brain, seen with ^{13}C MRS *in vivo*. *Alcohol Clin Exp Res* 31: 19A, *Suppl S*
162. Dominguez JE, **Mason GF**, Rothman DL, Czarkowski KA, Beyor S, Epperson CN (2007) Postpartum GABA concentration: early observations from the MoTHERS study. *Amer Psychiatric Assoc*, NR104
163. Valentine G, Mason GF, Krystal JH, Sanacora G (2007) Acute effects of Ketamine on mood and occipital cortex amino acid neurotransmitter content. *Biol Psychiatry* 61: 233S.
164. Herzog R, Jiang LH, **Mason G**, Rothman D, Behar K, Sherwin R (2007) Suppression of brain metabolism following prolonged exposure to recurrent hypoglycemia. *Diabetes* 56: A165-A166, *Suppl 1*
165. Boumezbeur F, **Mason GF**, de Graaf RA, Cline, GW, Behar, KL, Shulman, GI, Rothman, DL, Falk Petersen K (2008) Increased Glial Energy Metabolism during Normal Brain Ageing assessed by Dynamic ^{13}C NMR Spectroscopy. *Proc Intern Soc Magn Reson Med*, p. 374
166. Boumezbeur F, Falk Petersen K, **Mason GF**, Cline GW, Behar KL, Shulman GI, and Rothman DL (2008) Lactate Metabolism in Human Brain Measured by Dynamic ^{13}C MRS. *Proc Intern Soc Magn Reson Med*, p. 778
167. Boumezbeur F, de Graaf RA, **Mason GF**, Cline GW, Behar KL, Shulman GI, Rothman DL, Falk Petersen K (2008) Alterations of Brain Metabolites during Normal Aging: Correlation with Altered Energy Metabolism. *Proc Intern Soc Magn Reson Med*, p. 375
168. Patel AB, de Graaf RA, Rothman DL, Shulman RG, Behar KL, **Mason GF** (2008) NMR investigations of acetate transport and metabolism in the rat brain *in vivo*. *Proc Intern Soc Magn Reson Med*, p. 119
169. Boumezbeur F, Falk Petersen K, Cline GW, Shulman GI, Rothman DL, **Mason GF** (2008) Combination of Datasets from $[2-^{13}\text{C}]$ Acetate and $[1-^{13}\text{C}]$ Glucose Experiments Improve Accuracy of Metabolic Rates Determination in Humans. *Proc Intern Soc Magn Reson Med*, p. 196
170. Gunduz-Bruce H, Peixoto AJ, Moussai J, Bhagwagar Z, Watzl JQ, Rothman DL, Krystal JH, **Mason GF** (2008) Assessment of Human Brain Glutamate Using a Hyperosmolar Probe and ^1H -MRS. *American College of Neuropsychopharmacology*
171. Chowdhury GM, de Graaf RA, Jiang L, **Mason GF**, Rothman DL, Behar KL (2009) ^1H - ^{13}C MRS Ex Vivo Study of Cortical Ketone Body Utilization in Awake Rats During Fasting-Induced Ketosis. *Proc Intern Soc Magn Reson Med*, p. 2361
172. **Mason GF**, Watzl J, Weinzimer S, Sanacora G, Guidone E, Petrakis IL, Rothman DL, Krystal JH (2009) Acute Ethanol Alters GABA and Myoinositol in Human Brain. *Proc Intern Soc Magn Reson Med*, p. 433

173. De Feyter H, Petersen KF, **Mason GF**, Sanacora G, Krystal J, Gulanski B, Sherwin RS, Behar KL, de Graaf RA, Boumezbeur F, Shulman GI, Rothman DL (2009) ^{13}C MRS during $[3\text{-}^{13}\text{C}]$ lactate infusion under hyperinsulinemic-hypoglycemic conditions reveals compartmentalized lactate metabolism in human brain. *Proc Intern Soc Magn Reson Med*, p. 3238
174. Jiang L, Herzog R, **Mason GF**, de Graaf R, Rothman DL, Sherwin RS, Behar KL (2009) In vivo MRS studies of metabolic changes induced by recurrent antecedent hypoglycemia probed by $3\text{-}^{13}\text{C}$ -lactate. *Proc Intern Soc Magn Reson Med*, p. 3294
175. van Eijsden P, Behar KL, **Mason G**, Braun KPJ, de Graaf RA (2009) In vivo ^1H - $[^{13}\text{C}]$ MRS: A comprehensive tool to investigate the metabolic basis of brain function and disease. *Eur Paediatric Neurology Society Congress*
176. **Mason GF**, Kibbey RG, Pongratz RL, Cline GW (2009) Kinetic C-13-Isotopic Modeling of beta-Cell Mitochondrial Metabolism Concurrent with Glucose Stimulated Insulin Secretion (GSIS) *Diabetes* 58: A424.
177. **Mason GF**, Watzl J, Gomez R, Weinzimer S, Sanacora G, Guidone E, Petrakis IL, Rothman DL, Krystal JH (2009) Kinetics of brain GABA and ethanol during IV administration of ethanol. *Alcohol Clin Exp Res* 33 (Suppl 1): 233A
178. Gomez R, Watzl J, Behar KL, Weinzimer S, Sanacora G, Guidone E, Petrakis IL, Krystal JH, **Mason GF** (2009) Acute neurochemical effects of ethanol in humans. *American College of Neuropsychopharmacology*, p. 35
179. Sanacora G, Rothman D, Valentine G, Krystal J, **Mason G** (2009) Reduced occipital GABA synthesis rates in MDD. *American College of Neuropsychopharmacology*, p. 159